NZ615721B2 - Immunogenic compositions in particulate form and methods for producing the same - Google Patents
Immunogenic compositions in particulate form and methods for producing the same Download PDFInfo
- Publication number
- NZ615721B2 NZ615721B2 NZ615721A NZ61572112A NZ615721B2 NZ 615721 B2 NZ615721 B2 NZ 615721B2 NZ 615721 A NZ615721 A NZ 615721A NZ 61572112 A NZ61572112 A NZ 61572112A NZ 615721 B2 NZ615721 B2 NZ 615721B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- domain
- polypeptide
- blp
- lysm
- protan
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 230000002163 immunogen Effects 0.000 title claims abstract description 50
- 230000027455 binding Effects 0.000 claims abstract description 116
- 108050000721 LysM domain Proteins 0.000 claims abstract description 114
- 102000008826 LysM domain Human genes 0.000 claims abstract description 114
- 229920001184 polypeptide Polymers 0.000 claims abstract description 88
- 230000000890 antigenic Effects 0.000 claims abstract description 40
- 239000002245 particle Substances 0.000 claims abstract description 37
- 238000006384 oligomerization reaction Methods 0.000 claims abstract description 32
- 108010013639 Peptidoglycan Proteins 0.000 claims abstract description 30
- 230000001717 pathogenic Effects 0.000 claims abstract description 25
- 239000000969 carrier Substances 0.000 claims abstract description 24
- 241000894006 Bacteria Species 0.000 claims abstract description 20
- 210000004027 cells Anatomy 0.000 claims description 91
- 102000004169 proteins and genes Human genes 0.000 claims description 81
- 108090000623 proteins and genes Proteins 0.000 claims description 81
- 108010006232 Neuraminidase Proteins 0.000 claims description 48
- 102000005348 Neuraminidase Human genes 0.000 claims description 47
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 40
- 241000700605 Viruses Species 0.000 claims description 29
- 241000712461 unidentified influenza virus Species 0.000 claims description 22
- 238000005829 trimerization reaction Methods 0.000 claims description 17
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 208000006572 Human Influenza Diseases 0.000 claims description 12
- 206010022000 Influenza Diseases 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 241000711573 Coronaviridae Species 0.000 claims description 10
- 244000052769 pathogens Species 0.000 claims description 9
- 241000287828 Gallus gallus Species 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 7
- 208000001756 Virus Disease Diseases 0.000 claims description 6
- 238000006471 dimerization reaction Methods 0.000 claims description 5
- 230000000241 respiratory Effects 0.000 claims description 5
- 241000351643 Metapneumovirus Species 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 210000000845 Cartilage Anatomy 0.000 claims description 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 claims description 3
- 101700038997 GC Proteins 0.000 claims description 3
- 101700030336 GLYCP Proteins 0.000 claims description 3
- 241000194036 Lactococcus Species 0.000 claims description 3
- 101710041009 THBS1 Proteins 0.000 claims description 3
- 101700087068 VGLG Proteins 0.000 claims description 3
- 101700029964 WAC Proteins 0.000 claims description 3
- 101700075237 gG Proteins 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 229940039696 Lactobacillus Drugs 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 abstract description 5
- 101710043164 Segment-4 Proteins 0.000 description 93
- 101700038759 VP1 Proteins 0.000 description 93
- 101700005460 hemA Proteins 0.000 description 93
- 239000000185 hemagglutinin Substances 0.000 description 85
- 235000018102 proteins Nutrition 0.000 description 76
- 108020001507 fusion proteins Proteins 0.000 description 64
- 102000037240 fusion proteins Human genes 0.000 description 64
- 108060001039 GCN4 Proteins 0.000 description 56
- 229960005486 vaccines Drugs 0.000 description 54
- 102000038129 antigens Human genes 0.000 description 41
- 108091007172 antigens Proteins 0.000 description 41
- 239000000427 antigen Substances 0.000 description 39
- 230000004927 fusion Effects 0.000 description 28
- 210000003324 RBC Anatomy 0.000 description 25
- 210000002966 Serum Anatomy 0.000 description 22
- 102000004965 antibodies Human genes 0.000 description 22
- 108090001123 antibodies Proteins 0.000 description 22
- 230000000694 effects Effects 0.000 description 17
- 229940036185 Synagis Drugs 0.000 description 15
- 238000004166 bioassay Methods 0.000 description 14
- 238000001262 western blot Methods 0.000 description 13
- 230000004520 agglutination Effects 0.000 description 12
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 12
- 239000012228 culture supernatant Substances 0.000 description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- 210000002421 Cell Wall Anatomy 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 101710026031 dauD Proteins 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 102000004851 Immunoglobulin G Human genes 0.000 description 10
- 241000144282 Sigmodon Species 0.000 description 10
- 210000003743 Erythrocytes Anatomy 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 210000004072 Lung Anatomy 0.000 description 8
- 230000035492 administration Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 230000003612 virological Effects 0.000 description 8
- 102000013361 Fetuins Human genes 0.000 description 7
- 108060002885 Fetuins Proteins 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 230000035931 haemagglutination Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 210000004962 mammalian cells Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 7
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 7
- 206010001889 Alveolitis Diseases 0.000 description 6
- 101700039191 EGFR Proteins 0.000 description 6
- 108060003023 F Proteins 0.000 description 6
- 208000006897 Interstitial Lung Disease Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000007312 Recombinant Proteins Human genes 0.000 description 6
- 108010033725 Recombinant Proteins Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 108091007929 PDGF receptors Proteins 0.000 description 5
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 230000002708 enhancing Effects 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002035 prolonged Effects 0.000 description 5
- 230000001681 protective Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 239000000277 virosome Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 4
- 102100010782 EGFR Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- 229940088597 Hormone Drugs 0.000 description 4
- 210000003734 Kidney Anatomy 0.000 description 4
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 4
- 101710023234 Segment 5 Proteins 0.000 description 4
- 244000057717 Streptococcus lactis Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 235000020127 ayran Nutrition 0.000 description 4
- 230000001580 bacterial Effects 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000006143 cell culture media Substances 0.000 description 4
- 230000001419 dependent Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 230000000534 elicitor Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000001131 transforming Effects 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229940072417 Peroxidase Drugs 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 108090000437 Peroxidases Proteins 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000005591 charge neutralization Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 2
- 210000004899 C-terminal region Anatomy 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 229960001231 Choline Drugs 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000033180 ERVK-6 Human genes 0.000 description 2
- 101710038044 ERVK-6 Proteins 0.000 description 2
- 101710027967 ERVW-1 Proteins 0.000 description 2
- 102100016692 ESR1 Human genes 0.000 description 2
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 210000001331 Nose Anatomy 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 102100007812 PDGFA Human genes 0.000 description 2
- 108010046016 Peanut Agglutinin Proteins 0.000 description 2
- 229940067605 Phosphatidylethanolamines Drugs 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 241000144290 Sigmodon hispidus Species 0.000 description 2
- 210000002845 Virion Anatomy 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 159000000013 aluminium salts Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 238000004164 analytical calibration Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000010437 gem Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 101700051140 mltD Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003472 neutralizing Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- 102100007495 AR Human genes 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 108010045149 Archaeal Proteins Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000024969 Bacterial Proteins Human genes 0.000 description 1
- 210000001172 Blastoderm Anatomy 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000234 Capsid Anatomy 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 101710003845 EHR_05900 Proteins 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 1
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 1
- 241000194029 Enterococcus hirae Species 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 229940109526 Ery Drugs 0.000 description 1
- 102000027757 FGF receptors Human genes 0.000 description 1
- 108091008101 FGF receptors Proteins 0.000 description 1
- 108090001126 FURIN Proteins 0.000 description 1
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 1
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 101700054771 GCA Proteins 0.000 description 1
- 101700059415 GTF4 Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108091022077 Glycosyltransferases Proteins 0.000 description 1
- 102000019483 Glycosyltransferases Human genes 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 229940115931 Listeria monocytogenes Drugs 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 101700061402 MTRX Proteins 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 108060005523 NOP53 Proteins 0.000 description 1
- 240000008962 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710016786 P/C Proteins 0.000 description 1
- 101710038792 PALG1 Proteins 0.000 description 1
- 102100002481 PLEK Human genes 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 229920000970 Repeated sequence (DNA) Polymers 0.000 description 1
- 210000003660 Reticulum Anatomy 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 229940064914 Retrovir Drugs 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 101710042981 SHMT1 Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101710017884 Segment-8 Proteins 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100011242 THBS1 Human genes 0.000 description 1
- 102100003095 TNFRSF1A Human genes 0.000 description 1
- 101700023029 TY1A Proteins 0.000 description 1
- 101710010146 TY1A-LR1 Proteins 0.000 description 1
- 101710035630 TY2A-GR1 Proteins 0.000 description 1
- 101710009684 TY2A-LR2 Proteins 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 101700021643 VP4A Proteins 0.000 description 1
- 101700028070 VPX Proteins 0.000 description 1
- 102000001998 Viral Core Proteins Human genes 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 102000004640 Viral Envelope Proteins Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 101710006035 Zmob_1875 Proteins 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 229940001442 combination vaccines Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108010021168 endolysin Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 102000034387 fluorescent proteins Human genes 0.000 description 1
- 108091006031 fluorescent proteins Proteins 0.000 description 1
- 230000000799 fusogenic Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 101700033367 gtf3 Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 230000002434 immunopotentiative Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960001226 live attenuated influenza Drugs 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 101700069366 lytC Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 101700045377 mvp1 Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 230000003071 parasitic Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 108010026735 platelet protein P47 Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 108010061514 sialic acid receptor Proteins 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108091006090 transcriptional activators Proteins 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 108700000002 viral envelope protein Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- HUMHYXGDUOGHTG-HEZXSMHISA-N α-D-GalpNAc-(1->3)-[α-L-Fucp-(1->2)]-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)OC1O HUMHYXGDUOGHTG-HEZXSMHISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Abstract
Disclosed is an immunogenic composition in particulate form, comprising: i. a non-viable bacterium-like particle (BLP) obtained from a Gram-positive bacterium as particulate carrier; ii. oligomers of a recombinantly produced polypeptide attached non-covalently to said BLP, wherein the recombinant polypeptide comprises (a) an N- or C-terminal antigenic domain, comprising at least one surface exposed polypeptide of pathogenic or tumour origin, or antigenic part thereof, the antigenic domain being fused to (b) an oligomerization domain, said oligomerization domain being fused via (c) a linker domain to (d) a peptidoglycan binding domain consisting of a single copy of a LysM domain mediating the non-covalent attachment of the polypeptide to the BLP, and wherein the polypeptide as a whole contains only a single copy of a LysM domain; and iii. a pharmaceutical acceptable diluent or excipient. polypeptide comprises (a) an N- or C-terminal antigenic domain, comprising at least one surface exposed polypeptide of pathogenic or tumour origin, or antigenic part thereof, the antigenic domain being fused to (b) an oligomerization domain, said oligomerization domain being fused via (c) a linker domain to (d) a peptidoglycan binding domain consisting of a single copy of a LysM domain mediating the non-covalent attachment of the polypeptide to the BLP, and wherein the polypeptide as a whole contains only a single copy of a LysM domain; and iii. a pharmaceutical acceptable diluent or excipient.
Description
Title: Immunogenic compositions in particulate form and methods for producing the same.
The invention relates to the field of immunology and vaccine development, in
particular to the development of vaccines based on native antigen oligomers.
Many surface exposed proteins of pathogens and tumour cells are functional as
oligomers. Examples for pathogens are for example, influenza virus hemagglutinin (HA) which
occurs in virions as a homotrimer, and neuraminidase (NA) as a homotetramer. Also, the human
immunodeficiency virus (HIV) glycoproteins gp140/gp120 is a homotrimer in its active form.
se, the atory syncytial virus (RSV) glycoproteins G and F occur in virions as
tetrameric and trimeric homo-oligomers, respectively. Likewise, coronavirus spikes consist of
homotrimers as is the case for the human respiratory coronaviruses and for SARS coronaviruses.
Examples for tumour cells are for example, receptor tyrosine kinases . RTKs are the highaffinity
cell surface receptors for many polypeptide growth factors, cytokines, and hormones.
Growth factor receptors include: epidermal growth factor or, fibroblast growth factor
receptors and et-derived growth factor receptor. Hormone receptors include: en
or and estrogen receptor. An example of the epidermal growth factor receptor (EGFR) is the
ErbB protein family of four structurally related RTKs. The four members of the ErbB protein
family are capable of g homodimers, heterodimers, and possibly higher-order oligomers
upon tion by a subset of potential growth factor s. ErbB-1 is overexpressed in many
cancers. The platelet-derived growth factor receptor (PDGF) family consists of PDGF-A, -B, -C
and -D, which form either homo- or heterodimers (PDGF-AA, -AB, -BB, -CC, -DD). The four
PDGFs are inactive in their monomeric forms. Such oligomeric proteins of pathogens and tumour
cells are often involved in the pathogenicity and genicity of the disease-causing entity
(viruses, bacteria, parasites) or in cancer development, respectively, and are therefore important
targets for vaccine development.
However, during vaccine preparation the integrity and, hence, the antigenicity of these
oligomeric ures may be negatively affected e.g. if the cturing process involves
inactivation of the pathogen. atively, the oligomeric status of the antigen may not be obtained
due to the production process used for the manufacturing of (recombinant) t vaccines. In
both cases, this may result in aggregation or dissociation into a monomeric and/or misfolded state
of the proteins.
Conformational epitopes embedded in the quaternary structures of oligomers may
critically contribute to immunogenicity (Weldon et al. PLoS One 5 [2010], pii: e12466). Du et al.
(Virology 395 [2009], 33-44) e.g. found that immunization of rabbits provided no evidence that
trimerized gp140 constructs d icantly ed neutralizing antibodies to several HIV-
1 pseudoviruses, compared to gp140 lacking a trimerization motif. On the other hand, Grundner et
al . ogy 331 , 33–46) showed that immunization of rabbits with the gp140 trimer
elicited neutralizing antibodies of greater potency and h than did either gp120 or solid-phase
proteoliposomes containing a cleavage-defective Env. Also Wei et al. (J. Virol. 82 [2008], 6200-
6208) demonstrated that ic viral spikes serve as the optimal protein immunogens to elicit
neutralizing antibodies t H5N1 isolates. Of other note, Bosch et al. (J. Virol. 84 [2010],
10366-10374) provided evidence that the combination of soluble trimeric HA and eric NA of
pandemic swine-origin 2009 ) influenza virus in the presence of adjuvant provides
protection against infection in ferrets.
Therefore, it is vable that the presence of native oligomeric protein antigens in
es is pivotal for their protective capacity. In many instances, oligomerization is determined
by a subdomain having strong oligomerization properties. Also in many cases, such
oligomerization subdomain of vaccine ns is embedded in a membrane. To enable
oligomerization of vaccine subunit ns in the absence of a lipid environment, native
oligomerization subdomains can be substituted by a heterologous coiled-coil motif with similar
conformation-inducing properties. Examples of such motifs that have been successfully applied to
obtain native oligomeric protein structures are a 32-amino-acid form of the GCN4 transcription
factor (GCN), a 27-amino-acid trimerization domain from the C-terminus of bacteriophage T4
fibritin (T4F), and a soluble trimerization domain of chicken cartilage matrix (CART) protein
(Selvarajah et al., AIDS Res. Hum. Retrovir. 24 [2008] 301–314; Yang et al., J. Virol. 74 [2000],
5716–5725; Yang et al., J. Virol. 76 [2002], 4634–4642).
Hence, technology to produce native oligomeric subunit vaccine antigens is available.
Nevertheless, it is known that soluble subunit vaccine antigens are poorly immunogenic in general
and need adjuvants and/or a particulate carrier system in order to raise robust immune responses. In
the recent past there has been a growing interest in the development of novel non-replicating
antigen presentation systems in order to increase the immunogenicity of antigens that could be used
as vaccines. Many of these s are designed in such a way to present the antigen as a
polyvalent particulate structure. Some of the well appreciated es are those of hepatitis B
virus core and surface proteins cally fused to foot-and-mouth disease virus (FMDV) (Clarke
et al., Nature 330 [1987], 381-384) and HIV (Michel et al., Proc. Natl. Acad. Sci. USA 85 [1988],
7957-7961; Schlienger et al., J. Virol. 66 [1992], 2570-2576) antigens; the development of Ty virus
like particles (VLPs) as n carriers (Adams et al., Nature 329 [1987], 68-70) where antigens
are genetically fused to the C-terminus of the TYA gene encoded protein of the yeast retro-
transposon Ty to form hybrid Ty-VLPs, parvovirus like particles (Miyamura et al., Proc. Natl.
Acad. Sci. U S A 91 [1994], 8507-8511). These technologies ensure that the antigen in question is
presented in multiple copies in relatively large particles.
Other known particulate carriers for antigens are mes which are complexes
composed of lipids and at least one viral envelope protein, produced by an in vitro procedure. The
lipids are either purified from eggs or plants or produced synthetically, and a fraction of the lipids
originates from the virus providing the envelope protein. Essentially, virosomes represent
reconstituted, empty virus envelopes devoid of the capsid including the genetic material of
the source virus(es). mes are not able to replicate but are pure fusion-active vesicles. Known
virosomes for use as antigen carrier include virosomes termed immunopotentiating tituted
influenza virosomes ). IRIVs are cal, unilamellar vesicles with a mean diameter of 150
nm and comprise a double lipid membrane, consisting essentially of phospholipids, preferably
phosphatidylcholines (PC) and phosphatidylethanolamines (PE). IRIVs may contain the functional
viral envelope glycoproteins HA and NA intercalated in the phospholipid bilayer membrane. The
ically active HA does not only confer structural stability and homogeneity to virosomal
ations but also significantly contributes to the immunological properties by maintaining the
fusion activity of a virus.
Although these known technologies can e particulate carriers which enhance the
immunological properties of a vaccine preparation, the methodologies are typically rather
cumbersome and require specialized equipment and personnel. In addition, the use of viral material
as carrier is preferably to be avoided. Furthermore, none of the existing technologies have been
reported to be applied successfully in the manufacture of native oligomeric subunit vaccines.
Whereas it is known in the art (see e.g. WO 02/101026) to t an antigen to the
immune system by fusion to a peptidoglycan g sequence and attachment to particles derived
from a Gram-positive bacterium, this particulate carrier technology has thus far only been
described and applied in relation to the presentation of monomeric antigens.
WO 99/25836 and Bosma et al. (Appl. Environ. Microbiol. 72 [2006], 9) teach
that one LysM domain suffices to mediate n obtain binding to Gram-positive microorganisms
and/or peptidoglycan microparticles (BLPs, formerly called GEMs). This approach was for
example followed by Raha et al. (Appl. Environ. Microbiol. 68 [2005], 75-81) and Moeini et al.
(Appl. n. iol. 90 [2010], 77-88). However, antigen g via only a single LysM
domain is rather limited (Bosma et al.) and not very stable, as shown by Raha et al. (Figure 6) who
determined that approximately 30 to 45% of the initially bound antigen is lost after a storage period
of 5 days. In ent with that observation, Moeini et al. shows in Figure 6 that approximately
40% of the antigen bound through a single LysM domain is lost after a e period of 5 days.
The successful manufacturing of vaccines requires long term storage for several
months or mes even for years. The use of a single LysM binding domain results not only in
low binding yields (Bosma et al.) but also in low stability of the bound antigens (Raha et al.,
Moeini et al.). Thus, this approach is unsuitable for an economically viable vaccine production
process for BLP-based vaccines, which require optimal loading of antigens to the particles, i.e. high
loading yields, in combination with antigens that remain stably bound over a prolonged .
Prior to the present invention, the commonly held view to improve the efficacy and
stability of antigen binding was to increase the number of LysM domains. In fact, it was
demonstrated in the art that consecutive LysM domains in a single construct (2 to 3 domains in
line; in cis / intramolecular) provides the most optimal and stable g. See Figure 3 of Bosma
et al., showing a steep increase in binding affinity by the addition of a second LysM domain, and
the level was even higher than that of wild-type AcmA comprising 3 LysM domains in cis.
r, the present inventors observed that the ch of using two (or more) consecutive
LysM domains in a single construct does not yield the expected results in case of oligomeric
antigen binding. This is because the LysM tandem repeat mediates such a strong binding that not
only functional oligomers but also non-functional monomers are bound to the r. The presence
of non-functional rs in vaccines is highly undesirable because such a geneous
complex makes it more difficult and cumbersome to characterize formulated vaccines.
Furthermore, non-functional monomers containing LysM tandem repeats compete strongly with the
functional oligomers for the available binding sites on the BLPs. Most antly, non-functional
monomers in vaccines may impose a health risk for the vaccinated subject since it is known in the
art that non-functional, improperly folded antigens can induce a detrimental immune se.
The inventors therefore aimed at providing stable native oligomeric subunit es
not only having improved immunogenicity but which can also be produced in a relatively easy and
economically attractive manner. In particular, it was an object to increase the safety and efficacy of
(current) vaccines in a simple and reliable manner while avoiding the use of pathogenic or
otherwise unsafe starting materials; and/or to provide the public with a useful choice.
It was singly found that preferential g of functional oligomers is obtained
if antigens are fused to only a single LysM domain in combination with an oligomerization domain
(OMD) (see Figure 2). The ation of a single LysM domain fused via a linker sequence to an
oligomerization domain minimizes the presence of ed non-functional improperly folded
antigens in the vaccine, thereby enhancing the safety of the vaccine. Moreover, vaccines with BLP
bound oligomers made from antigens that contain a single LysM domain and an OMD showed a
high stability upon prolonged storage (see Figure 5).
Without wishing to be bound by theory, it s that the addition of the OMD
enhances the g teristics of the single LysM domains, supposedly h
intermolecular ctions of multiple molecules in the oligomer, to a similar level as is achieved
through intramolecular interactions for multiple LysM domains in a single molecule. Presumably,
when using a single LysM domain, in a mixture of functional oligomeric ns and nonfunctional
monomers, the oligomers bind preferentially to the BLPs because the single LysM
domain in a monomer configuration has only weak BLP binding properties. On the other hand, the
single LysM domains of each individual molecule in an oligomeric configuration have been
brought into such close proximity (in trans) of each other (by virtue of the OMD) that a high
binding functionality is obtained which is comparable to two or more LysM domains in a single
molecule. Hence, the surprising t underlying the present invention is that a single LysM
domain per subunit when assembled into one oligomeric molecule by the use of an OMD allows
for a preferential binding of the desired native eric antigen, which is not possible if the
OMD is omitted or two or more molecular) LysM domains are used.
The present finding also enables the selective binding of the desired native oligomers
from a mixture solution of oligomers and monomers, since monomers with a single LysM domain
show very poor binding and oligomers with a single LysM domain bind very efficiently. This
selective binding of oligomers from a mixed solution of oligo- and monomers is not possible if two
or more LysM binding domains are used, since efficient g is in those cases observed for both
mono- and oligomers, or monomers even bind more efficiently.
As an illustration, in order to bind oligomeric subunit antigens in their native
conformation to the particles, the influenza HA and NA antigens and the respiratory syncytial virus
F antigen were each fused to the GCN4 domain and via a linker to a peptidoglycan binding domain
n) (from N- to C-terminus: HA-GCN4-Protan and Protan-GCN4-NA; F-GCN4-Protan). The
HA-GCN4-Protan, F-GCN4_Protan and Protan-GCN4-NA fusions produced in human nic
kidney (HEK293) cells rendered s, trimers and tetramers, respectively, that were also able to
bind to said peptidoglycan carrier particles (BLPs). Similar tions were done using Chinese
hamster ovary cells and insect cells. Functionality of the HA oligomer lized on the particles
was demonstrated in a haemagglutination assay performed with said particles. Immunogenicity of
the said les loaded with said HA oligomer was demonstrated in a mouse model.
Immunogenicity of the particles loaded with F oligomer was demonstrated in a mouse model and
efficacy was demonstrated in a cotton rat model.
The present disclosure accordingly relates to a recombinant polypeptide comprising:
A) an N- or C-terminal antigenic domain, comprising at least one surface exposed
polypeptide (e.g. of pathogenic or tumour cell origin) or antigenic part thereof, the antigenic
domain being fused to
B) an oligomerization domain (OMD), said erization domain being fused via
C) a linker domain to
D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain
capable of mediating the non-covalent attachment of the polypeptide to a peptidoglycan carrier
particle being a non-viable bacterium-like particle (BLP) obtained from a Gram-positive
ium, and n the polypeptide as a whole contains only a single copy of a LysM
In particular, in a first embodiment, the invention provides an immunogenic composition
in particulate form, comprising:
i. a non-viable bacterium-like particle (BLP) obtained from a Gram-positive bacterium as
particulate carrier;
ii. oligomers of a inantly produced polypeptide attached non-covalently to said BLP,
wherein the inant polypeptide comprises:
A) an N- or C-terminal antigenic domain, comprising at least one surface exposed
polypeptide of pathogenic or tumour origin, or antigenic part thereof, the
nic domain being fused to
B) an oligomerization domain (OMD), said oligomerization domain being fused via
C) a linker domain to
D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM
domain mediating the non-covalent attachment of the polypeptide to the BLP,
and wherein the polypeptide as a whole contains only a single copy of a LysM
; and
iii. a pharmaceutically acceptable diluent or excipient.
The concept of the invention thus relies on the cted finding that, for efficient
and ive binding of oligomeric fusion proteins to a carrier particle, it is advantageous to use an
oligomerization domain in combination with only a single copy of a binding domain which in
nature is part of a repeated structure sing multiple copies of the binding domain. For
example, for binding to particles of other carrier entities, such as virosomes, liposomes or particles
based on sugar polymers, having similar binding partners (e.g. derived from enzymes that degrade
such particles), a fusion protein can be engineered comprising a non-repeating binding domain in
an oligomer construct. Examples of other repeated binding domains from which a single copy can
be used to bind to r entities in combination with an oligomerization domain include the
following:
- Choline binding domains from e.g. autolysins such the pneumococcal enzymeLytA
(e.g. Pfam PF01473) for binding to carriers that contain choline.
- Glucan binding s from e.g. glycosyltransfer ases such as glucansucrases of
oral streptococci (e.g. Pfam 3) for the binding to particles ed of glucose containing
polymers.
- Phosphatidylinositol lipid binding domains, e.g. the Pleckstrin homology (PH)
domains (Pfam PF00169).
Antigenic Domain
The sion “surface exposed polypeptide or antigenic part thereof’’ is meant to
refer to any stretch of amino acids which is found to be surface exposed in its l context e.g.
as part of a en or on a tumour cell, and which is capable of mounting a protective immune
response. Known or yet to be ered antigenic sequences of pathogenic or tumour origin may
be used in the present invention. The surface exposed pathogenic polypeptide is for example of
viral, bacterial, or parasitic origin. In a preferred embodiment, it is a viral protein. For example, a
surface exposed polypeptide of pathogenic origin comprises an ectodomain of an ped virus
protein, or antigenic part thereof. Exemplary enveloped viruses include influenza virus,
coronavirus, human respiratory coronaviruses, human immunodeficiency virus (HIV),
metapneumovirus, xovirus, in particular respiratory syncytial virus (RSV). In a specific
aspect, the surface d polypeptide or antigenic part thereof is selected from the group
ting of nza hemagglutinin ectodomain or part thereof, influenza neuraminidase
ectodomain or part thereof, coronavirus spike (S) protein ectodomain or part thereof, RSV
glycoprotein F ectodomain or part thereof, HIV gp140 or part thereof and RSV glycoprotein G
ectodomain or part thereof.
Exemplary antigens from tumour cells include receptor tyrosine kinases (RTKs).
RTKs are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines,
and hormones. Growth factor receptors include: epidermal growth factor receptor, fibroblast
growth factor ors and platelet-derived growth factor receptor. e ors include:
androgen receptor and estrogen receptor. An example of the mal growth factor receptor
(EGFR) is the ErbB protein family of four structurally related RTKs. The four members of the
ErbB protein family are capable of forming homodimers, heterodimers, and possibly -order
oligomers upon tion by a subset of potential growth factor ligands. ErbB-1 is overexpressed
in many cancers. The platelet-derived growth factor receptor (PDGF) family consists of PDGF-A, -
B, -C and -D, which form either homo- or heterodimers (PDGF-AA, -AB, -BB, -CC, -DD). The
four PDGFs are inactive in their monomeric forms.
Peptidoglycan binding domain
A ptide described herein is characterized by the presence of only a single copy
of a LysM (Lysin motif) domain e of mediating polypeptide binding to peptidoglycan. The
LysM domain, also referred to in the art as ‘’LysM repeat’’, is about 45 residues long. It is found in
a y of enzymes involved in bacterial cell wall ation (Joris et al., FEMS Microbiol. Lett.
70 [1992], 257-264; Andre et al., J. Bacteriol. [2008], 7079-7086). The LysM domain is assumed
to have a l peptidoglycan binding function. The structure of this domain is known (‘The
structure of a LysM domain from E. coli membrane-bound lytic murein transglycosylase D (MltD).
Bateman and Bycroft, J. Mol. Biol. 299 [2000], 119). The presence of the LysM domains is
not limited to bacterial proteins. They are also present in a number of eukaryotic proteins, whereas
they are lacking in archaeal proteins. A cell wall binding function has been postulated for a number
of proteins containing LysM domains. Partially purified muramidase-2 of Enterococcus hirae, a
protein similar to AcmA and ning six LysM domains, binds to peptidoglycan fragments of
the same strain. The p60 protein of Listeria monocytogenes contains two LysM domains and was
shown to be associated with the cell surface. The muropeptidases LytE and LytF of Bacillus
subtilis have three and five repeats, respectively, in their N-termini and are both cell wall-bound.
It is important to note that previous studies, e.g. WO99/25836 in the name of the
applicant and Bosma et al. (Appl. Environm. Microbiol. 72 [2006], 880-889) indicated that a single
LysM domain is very poor in binding to BLPs and that increasing the number of LysM s
enhanced binding to BLPs. This is in line with the fact that most naturally occurring peptidoglycan
g proteins contain multiple (e.g. 2-6) tandem repeats of a LysM domain. In contrast, it was
found in the present invention that binding of native oligomeric protein antigens to a particulate
carrier is most efficient if only a single LysM domain is used in combination with an
oligomerization domain (OMD), provided that a linker sequence is present between the OMD and
the LysM .
A d person will be able to identify a LysM domain amino acid sequence (Buist et
al ., Mol. Microbiol. 68 [2008], 838-847; waran et al., Appl. iol. Biotechnol. 92
, 921-928) by conducting a homology-based search in publicly available protein ce
databases using methods known in the art. The PFAM website provides two profile hidden Markov
models (profile HMMs) which can be used to do sensitive database searching using statistical
descriptions of a sequence family's sus. HMMER is a freely distributable implementation of
profile HMM software for protein sequence analysis. As used , the term ‘’LysM domain’’
typically refers to an amino acid sequence showing at least 50%, preferably at least 60%, most
ably at least 70% sequence similarity to the sequence according to PFAM accession number
PF01476 for the LysM domain (see http://www.sanger.ac.uk/cgi-bin/Pfam/getacc?PF01476).
Numerous binding assays have been described in the art which allow the skilled
person to determine whether a LysM domain has the required oglycan binding ty. As
also described herein below, host cells can be transfected with the construct to be evaluated after
which the host cells are d to s and secrete the recombinant polypeptide of interest in
the culture supernatant.
Secreted proteins are then d for ive binding to peptidoglycan particle
obtained from a Gram-positive bacterium (bacterium-like particle or BLP) prepared by a well
established acid treatment procedure. For example, 0.15 mg BLPs (dry weight) are contacted with
an excess of cleared mammalian host cell expression culture supernatant and ted for 30
minutes at room temperature while mixing gently. BLPs with bound protein are then collected by
low-speed centrifugation. The pellet is analyzed for polypeptide bound to BLPs by SDS-PAGE and
n blotting using the appropriate antiserum. The amount of BLP-bound protein may be
determined and quantified by SDS-PAGE and uent Coomassie blue staining using e.g.
purified BSA as a reference protein.
As another example, fusions with (green) fluorescent protein can be prepared whose
binding behaviour to the surface of Lactococcus can be assayed. See for instance Hu et al., Appl.
n. Microbiol. 8 [2010], 2410-2418.
In one embodiment, a polypeptide described herein contains only a single copy of a
LysM domain found in the C-terminal region of the major autolysin AcmA of L. lactis which
contains three homologous LysM domains separated by mologous sequences (Protan). The
C-terminal region of AcmA was shown to mediate peptidoglycan binding of the sin (Buist et
al ., J. Bacteriol. 177 , 1554-1563). For the amino acid sequences of the three AcmA LysM
domains see for example Figure 2 in WO99/25836 (wherein the three LysM domains are indicated
by R1, R2 and R3), herein incorporated by reference.
Variations within the exact amino acid sequence of an AcmA LysM domain are also
comprised, under the provision that the peptidoglycan binding functionality is maintained. Thus,
amino acid tutions, deletions and/or insertions may be performed without losing the
peptidoglycan binding capacity. Some parts of the AcmA LysM domains are less suitably varied,
for instance the conserved GDTL, N and GQ motifs found in most LysM domains. Others may
however be altered without affecting the efficacy of the LysM domain to bind the carrier. For
example, amino acid residues at positions which are of very different nature (polar, apolar,
hydrophilic, hydrophobic) amongst the three LysM domains of AcmA can be modified. Preferably,
the polypeptide of the invention comprises a ce that is at least 70%, preferably 80%, more
preferably 90%, like 92%, 95%, 97% or 99%, identical to one of the three LysM domains of L.
lactis AcmA.
The ntage of amino acid sequence identity’ for a polypeptide, such as 70, 80, 90,
95, 98, 99 or 100 percent sequence identity may be determined by comparing two optimally
aligned sequences over a comparison window, wherein the portion of the polypeptide sequence in
the comparison window may include additions or deletions (i.e. gaps) as compared to the reference
sequence (which does not se ons or deletions) for optimal alignment of the two amino
acid sequences. The percentage is calculated by: (a) determining the number of positions at which
the identical amino acid occurs in both sequences to yield the number of matched positions; (b)
dividing the number of d positions by the total number of positions in the window of
comparison; and (c) multiplying the result by 100 to yield the tage of sequence identity.
Optimal alignment of sequences for comparison may be conducted by computerized
implementations of known algorithms, or by inspection. y ble sequence comparison
and multiple ce alignment algorithms are, respectively, the Basic Local Alignment Search
Tool (BLAST) (Altschul et al., J. Mol. Biol. 215 [1990], 403; Altschul et al., Nucleic Acid Res. 25
, 3389-3402) and lW programs both available on the et.
As another example, the LysM domain sequence from Lactobacillus fermentum
iophage Endolysin (Hu et al., Appl. Environ. Microbiol., 76 [2010], 2410-2418) or a
sequence showing at least 70% sequence identity thereto may also be used in the present invention.
Oligomerization Domain
As described above, a polypeptide described herein is characterized by the presence of
a oligomerization domain (OMD) and a single LysM domain. The OMD is for example a
dimerization, trimerization or tetramerization domain. Such domains are known in the art (O’Shea
et al., Science 243 [1989], 534-542; Harbury et al., e 262 [1993], 1401–1407). For example,
the oligomerization domain is a GCN4-based dimerization, trimerization or tetramerization
domain. The e zipper region of the yeast transcriptional activator GCN4 comprises the
GCN4-p1 dimerization domain with amino acid sequence
MKQLEDKVEELLSKNYHLENEVARLKKLVGER. A GCN4-based trimerization domain
(GCN4-pII) preferably comprises the amino acid sequence
MKQIEDKIEEIESKQKKIENEIARIKK.
The term “tetramerization domain” as used herein is defined as a domain that mediates
the formation of a tetramer out of four monomeric proteins or parts thereof. Suitable
erization domains include, but are not limited to, the Sendai virus phosphoprotein
tetramerization domain and a tetramerization domain (GCN4-pLI) derived by mutation from the
yeast GCN4 dimerization domain. In a preferred embodiment, tetramerization of a recombinant
nza neuraminidase ectodomain or part thereof is provided by a GCN4-based tetramerization
domain. A ased tetramerization domain preferably ses the amino acid sequence
KLEEILSKLYHIENELARIKKLLGE.
Other useful oligomerization domains for use herein include the inal domain
sequence of bacteriophage T4 fibritin (foldon) or functional part or analog thereof, in particular the
inal 27 to 30 es of foldon (Güthe et al. J. Mol. Biol. 337 [2004], 905-915), and the
soluble trimerization domain of chicken cartilage matrix (CART) protein. The C-terminal
oligomerization domain of chicken age matrix protein is a trimeric coiled coil comprised of
three identical 43-residues (Selvarajah et al. AIDS Res. Hum. Retroviruses, 24 [2008], 301-314).
The oligomerization domain for use in the methods described herein may furthermore
include a double cysteine motif in between the antigenic domain and the coiled-coil motif in order
to further stabilize oligomeric proteins (Louis et al., J. Biol. Chem. 278 [2003], 20278-20286;
Magro et al., Proc. Natl. Acad. Sci. USA 109 [2012], 3089-3094).
Linker Domain
The examples herein below illustrate the ance of a linker domain for optimal
functioning of the OMD and/or the LysM domain. Accordingly, the OMD and LysM are preferably
separated by a linker domain consisting of between 10 and 60, ably 20-50, more preferably
-40 amino acid es. Direct fusion of the OMD to the LysM domain yielded unfavourable
results. Very good results were obtained using a linker domain having a length of about 30 (e.g. 28-
32) amino acids. See e 2 for details.
In one aspect, the linker domain comprises a linker sequence which is found in
between the LysM repeats in the C-terminus of L. lactis AcmA. For example, L1:
GASSAGNTNSGGSTTTITNNNSGTNSSST (29 amino acids);
L2: GSASSTNSGGSNNSASTTPTTSVTPAKPTSQ (31 amino acids) or
L3: QSAAASNPSTGSGSTATNNSNSTSSNSNAS (30 amino acids). In a preferred embodiment,
the linker domain consists of GASSAGNTNSGGSTTTITNNNSGTNSSST,
GSASSTNSGGSNNSASTTPTTSVTPAKPTSQ or
QSAAASNPSTGSGSTATNNSNSTSSNSNAS. Other linker domain ces of a correct length
(i.e. between about 10 and 60 amino acid residues) may also be used. The skilled person will be
able to produce and assess the suitability of a given linker sequence based on the Examples shown
below and his general knowledge.
It was furthermore found that the production of a polypeptide described herein can be
enhanced by the presence of a terminal ‘’capping domain’’. For example, expression of a construct
consisting of, from N- to inus, HA fused via an OMD and a linker ce to a single
LysM domain was sed upon the addition of a C-terminal capping domain (see Fig. 2A).
Hence, a polypeptide of the invention may rmore comprise in case of an N-terminal antigenic
domain a C-terminal capping domain, or in case of a C-terminal antigenic domain an N-terminal
capping . The capping domain may vary in length e.g. from about 10 to about 60 amino
acids, preferably 20-50, more preferably 25-40 amino acid residues, in length. Very good results
were obtained with a capping domain having a sequence identical to the linker domain connecting
the OMD to the LysM . In other words, the single copy LysM domain in a polypeptide of
the invention is advantageously flanked by identical or at least highly (>90%) similar amino acid
sequences. Accordingly, in a ic ment the capping domain, and preferably also the
linker domain, consists of an amino acid sequence selected from the group consisting of :
GASSAGNTNSGGSTTTITNNNSGTNSSST, SASSTNSGGSNNSASTTPTTSVTPAKPTSQ and
NPSTGSGSTATNNSNSTSSNSNAS.
The relative orientation of the various domains within the polypeptide can vary,
ed that a linker domain sequence is always located between the OMD and LysM domain.
le linker domains are described herein above.
In one embodiment, the LysM domain is located C-terminally from the polypeptide of
pathogenic origin or antigenic part thereof. For instance, this configuration is particularly suitable
for substances comprising type 1 membrane proteins such as influenza virus HA, HIV gp140,
coronavirus S en RSV F. In another embodiment, the LysM domain is located N-terminally from
the polypeptide of enic origin or antigenic part thereof. The latter orientation is preferred for
type 2 membrane proteins like influenza virus NA and RSV G. The polypeptide may furthermore
contain one or more sequences tating recombinant expression in and/or secretion by a
eukaryotic host cell. Advantageous sequences include N-terminal signal sequences. A “signal
sequence” is herein defined as a signal e that directs transport of a protein or part thereof to
the endoplasmic reticulum of a eukaryotic cell - the entry site of the ory pathway. A signal
sequence can be located N-terminal of the n or part thereof. Signal peptides can be cleaved
off after insertion of the n into the asmic reticulum. For example, in one embodiment a
pMT/BiP vector for expression of inant protein in Drosophila cells comprises a BiP signal
sequence. In another embodiment, a pCD5 vector for expression of recombinant protein in
mammalian cells comprises the signal sequence MPMGSLQPLATLYLLGMLVA, for instance the
signal peptide ce of CD5 glycoprotein. In yet another embodiment, the signal sequence
naturally preceding the protein is used to direct the precursor polypeptide to the secretory pathway.
As described herein above, a recombinant polypeptide described herein produced is
suitably used for the manufacture of an immunogenic composition in particulate form. A further
aspect therefore relates to an immunogenic composition in particulate form, comprising as
particulate carrier a non-viable spherical peptidoglycan le obtained from a Gram-positive
bacterium (GEM particle or ium-like particle (BLP)), wherein oligomers of recombinantly
produced ptides are attached non-covalently to said BLP, each polypeptide being defined as
herein above, and a pharmaceutically acceptable diluent or excipient.
BLPs are non-living, deprived of intact surface proteins and intracellular content
which can be obtained by treating intact cells with a solution capable of removing cell-wall
components such as a protein, (lipo)teichoic acid or carbohydrate from said cell-wall material
t mechanical disruption and wherein the thick peptidoglycan cell wall remains intact. The
resulting essentially spherical peptidoglycan microparticles reflect the size and shape of the sitive
ium. Preferably, the bacterium is a non-pathogenic bacterium, more preferably a
rade bacterium. The bacterium can be selected from the group consisting of a Lactococcus , a
Lactobacillus , a Bacillus and a Mycobacterium ssp.
Various embodiments are envisaged, for example the particulate r can be
provided valently with at least a first oligomer of polypeptides comprising surface exposed
polypeptides or antigenic parts thereof derived from a first pathogen and with a second oligomer of
polypeptides comprising distinct surface exposed polypeptides or antigenic parts thereof derived,
e.g. from the same or from a second, ct en. The distinct oligomers for instance
comprise different HA serotypes, HA and NA, HA and S and/or RSV F. The RSV F protein or an
immunogenic active fragment thereof having at least 10 amino acid residues is the preferred one in
terms of mediating protective antibody responses against RSV. The F n remains highly
conserved across both major strains of RSV (subgroup A and subgroup B). The F protein is
synthesized as a non-fusogenic 67 kDa precursor (F0) that undergoes proteolytic cleavage by furin
to e two disulfide-linked polypeptides, F1 and F2. The F protein enters the cell membrane
via the N-terminus of the F 1 polypeptide, whereas the transmembrane segment is located close to
the C-terminus. Adjacent to these two s are two heptad repeat sequences, denoted HR-C and
HR-N, that form a stable trimer of hairpin-like structures that undergo a conformational change to
enable the viral and cell membranes to be apposed before viral entry. In a red embodiment
the F ectodomain contains two mutated cleavage sites resulting in a non-cleaved polypeptide
locked in a prefusion mation.
In a preferred embodiment, the immunogenic composition is in particulate form,
comprising oligomers of a surface exposed ptide of influenza virus , or antigenic part
thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically
acceptable diluent or excipient. An immunogenic composition described herein for instance
comprises one recombinant trimeric influenza hemagglutinin ectodomain or part thereof or one
recombinant tetrameric influenza neuraminidase ectodomain or part thereof. Such immunogenic
composition is particularly suitable for eliciting an immune se in an individual against an
influenza virus subtype or strain, or more than one related influenza virus es or s. In
some embodiments however, an immunogenic composition described herein comprises a
combination of one or more trimeric hemagglutinin ectodomains or parts thereof, and/or one or
more eric neuraminidase ectodomains or parts thereof.
Thus for example, 2, 3, 4, 5, 6, 7, 8, 9 or 10 trimeric hemagglutinin ectodomains or
parts thereof can be combined, such as H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13,
H14, H15 and/or H16, or 2, 3, 4, 5, 6, 7, 8 or 9 tetrameric neuraminidase mains or parts
thereof can be combined, such as N1, N2, N3, N4, N5, N6, N7, N8 and/or N9. Additionally, an
immunogenic composition described herein may comprise a combination of one or more trimeric
hemagglutinin ectodomains or parts thereof and one or more tetrameric neuraminidase ectodomains
or parts thereof of different influenza subtypes. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 trimeric
hemagglutinin ectodomains or parts thereof and 1, 2, 3, 4, 5, 6, 7, 8 or 9 tetrameric neuraminidase
ectodomains or parts thereof can be combined, such as H1, H2, H3, H4, H5, H6, H7, H8, H9, H10,
H11, H12, H13, H14, H15, H16, N1, N2, N3, N4, N5, N6, N7, N8 and/or N9 . It will be clear to a
skilled person that the term “one or more ectodomains” asses one or more ectodomains
from one or more influenza virus subtypes, such as for example Influenza A virus and Influenza B
virus. Thus, an immunogenic composition in particulate form described herein can be a alent
ition with which an improved tion against an influenza virus infection can be
achieved as compared to an immunogenic composition comprising one inant trimeric
influenza hemagglutinin ectodomain or part f or one recombinant tetrameric influenza
neuraminidase ectodomain or part thereof. Additionally, or alternatively, with a multivalent
composition a wider protection against more than one influenza virus type, or influenza virus
subtypes or strains can be achieved. Furthermore, an immunogenic composition described herein
may be less sensitive to antigenic alterations than traditional vated or live attenuated influenza
virus vaccines.
A second embodiment of the invention relates to a method for providing an
immunogenic composition in particulate form, comprising the steps of : (a) providing a
inant polypeptide according to the invention; (b) providing a non-viable spherical
peptidoglycan particle obtained from a Gram-positive bacterium (BLP); (c) allowing for noncovalent
binding of said polypeptide to said BLP to form an immunogenic complex comprising
oligomers of a ptide comprising a surface exposed polypeptide of pathogenic or tumour
origin or antigenic part thereof bound non-covalently to a particulate carrier, and (d) formulating
the immunogenic complex into an immunogenic composition.
As to step (b), means and methods for providing peptidoglycan microparticles (BLPs)
are bed in the art. See for example WO 02/101026 and US 6,896,887 disclosing a method for
obtaining cell-wall material of a Gram-positive bacterium comprising treating said cell-wall
material with a solution capable of removing a cell-wall component such as a protein, teichoic
acid or carbohydrate from said cell-wall al wherein said cell-wall material ially
comprises spherical peptidoglycan microparticles. The particles thus obtained can simply be mixed
with a ation (e.g. a cell culture supernatant or purified polypeptide) comprising
recombinantly produced polypeptide(s). By virtue of their LysM domain and OMD, the
polypeptides can bind to a carrier, the binding being accompanied, preceded and/or followed by
ly into their native oligomeric configuration.
Also described is a nucleic acid ce encoding a polypeptide described herein, as
well as a vector comprising the nucleic acid sequence. The term “vector” as used herein is defined
as a nucleic acid molecule, such as a plasmid, bacteriophage or animal virus, capable of introducing
a heterologous nucleic acid ce into a host cell. A vector bed herein allows the
expression or production of a protein or part f encoded by the heterologous nucleic acid
sequence in a host cell. Vectors suitable in a method described herein include, but are not limited
to, pCD5 (Pouyani and Seed, Cell 83 , 3) and pCAGGS (Niwa et al., Gene 108
, 193-199). A “host cell” is a cell which has been transformed, or is capable of
transformation, by a nucleic acid molecule such as a vector. The term “transformation” is herein
defined as the uction of a foreign nucleic acid into a recipient cell. Transformation of a
recipient cell can result in transient expression of a recombinant protein by said cell, meaning that
the recombinant n is only expressed for a defined period of time. Alternatively,
transformation of a recipient cell can result in stable sion, meaning that the nucleic acid is
introduced into the genome of the cell and thus passed on to next generations of cells. Additionally,
inducible expression of a recombinant protein can be achieved. An inducible expression system
requires the presence or absence of a molecule that allows for expression of a c acid sequence
of interest. Examples of inducible expression systems include, but are not limited to, Tet-On and
Tet-Off expression systems, hormone inducible gene expression systems such as for instance an
ecdysone inducible gene expression system, an arabinose-inducible gene sion system, and a
Drosophila inducible expression system using a pMT/BiP vector (Invitrogen) which comprises an
inducible metallothioneine promoter.
A still further embodiment relates to a host cell comprising a nucleic acid sequence or
a vector described , with the o that said host cell is not present in a human. Such a host
cell is advantageously used for the recombinant tion of a polypeptide disclosed herein.
A recombinant polypeptide bed herein is for instance expressed in a prokaryotic
cell, or in a eukaryotic cell, such as a plant cell, a yeast cell, a mammalian cell or an insect cell.
onally a inant eric ectodomain or part thereof as described herein can be
expressed in plants. Prokaryotic and eukaryotic cells are well known in the art. A prokaryotic cell is
for instance E. coli or L. lactis. Examples of plants and/or plant cells include, but are not limited to,
corn (cells), rice (cells), ed(cells), tobacco (cells, such as BY-2 or NT-1 cells), and
potato(cells). Examples of yeast cells are Saccharomyces and Pichia . Examples of insect cells
e, but are not limited to, tera frugiperda cells, such as Tn5, SF-9 and SF-21 cells, and
Drosophila cells, such as Drosophila Schneider 2 (S2) cells. Examples of mammalian cells that are
suitable for expressing a recombinant protein described herein include, but are not limited to,
African Green Monkey kidney (Vero) cells, baby hamster kidney (such as BHK-21) cells, Human
retina cells (for example PerC6 cells), human embryonic kidney cells (such as HEK293 cells),
Madin Darby Canine kidney (MDCK) cells, Chicken embryo fibroblasts (CEF), Chicken embryo
kidney cells (CEK cells), blastoderm-derived embryonic stem cells (e.g. EB14), mouse embryonic
fibroblasts (such as 3T3 , Chinese hamster ovary (CHO) cells, and mouse myelomas (such as
NS0 and SP2/0), and derivatives of these cell types. In a preferred embodiment mammalian CHO
cells or S2 insect cells are used.
Also described is a method for providing a recombinant polypeptide described herein,
comprising culturing a host cell described above in a suitable , allowing for expression of
the polypeptide and isolating the substance. Preferably, the method uses a eukaryotic host cell,
preferably a mammalian host cell, for example an MDCK, HEK, CHO or PerC6 cell, or an insect
cell, for example an S2 cell.
Also described is a method for eliciting an immune response t a pathogen in
a mammalian individual comprising administering to said individual an immunogenic composition
described herein.
Also described are genic compositions which may be used as vaccines.
These vaccines may either be prophylactic (i.e. to prevent infection) or therapeutic (i.e. to treat
infection), but will typically be prophylactic. Also described is a method for raising an immune
response in a mammal comprising the step of administering an effective amount of an
immunogenic composition described herein. The immune response is preferably protective and
ably involves antibodies and/or cell-mediated immunity. The method may raise a booster
response. The mammal is ably a human. Where the vaccine is for prophylactic use, the
human is ably a child (e.g. a r or infant) or a teenager; where the vaccine is for
therapeutic use, the human is preferably a teenager or an adult. A vaccine intended for children
may also be administered to adults e.g. to assess safety, dosage, immunogenicity, etc. Vaccines
prepared according to the methods described herein may be used to treat both children and adults.
Thus a human t may be less than 1 year old, less than 5 years old, 1-5 years old, 5-15 years
old, 15-55 years old, or at least 55 years old. Preferred ts for receiving the es are the
elderly (e.g. >50 years old, >60 years old, and ably >65 years). The vaccines are not suitable
solely for these age groups, however, and may be used more lly in a population, including
for the young (e.g. <5 years old), hospitalised patients, healthcare workers, armed service and
military personnel, pregnant women, the chronically ill, or immunodeficient patients.
For example, also bed is a method for eliciting an immune response against a
viral disease in an individual, preferably wherein the viral disease is caused by influenza virus,
animal coronavirus, human respiratory coronaviruses, human immunodeficiency virus (HIV), or
paramyxovirus, in particular respiratory syncytial virus (RSV) or metapneumovirus. The method
involves administering to said individual a native oligomeric subunit e of the invention
comprising a:
A) an N- or C-terminal antigenic domain, comprising at least one surface d
polypeptide of pathogenic origin or antigenic part thereof, selected from the group
consisting of influenza hemagglutinin (HA) ectodomain or part thereof, influenza
neuraminidase (NA) ectodomain or part f, coronavirus spike (S) protein
ectodomain or part thereof, RSV glycoprotein F or G ectodomains or parts thereof and
HIV gp140 ectodomain or part thereof, the antigenic domain being fused to
B) an oligomerization domain (OMD), said oligomerization domain being fused via
C) a linker domain to
D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain
capable of mediating the non-covalent attachment of the polypeptide to a non-viable
bacterium-like particle (BLP) obtained from a Gram-positive bacterium, and n
the ptide as a whole contains only a single copy of a LysM domain.
The composition described herein can be stered by any way known by the
man skilled in the art, with preferences for nasal, gual, oral or parenteral administration
routes. In a preferred embodiment, the route of administration is the nasal route. Also described is a
delivery device pre-filled with an immunogenic composition of the invention. Suitable delivery
devices include pre-filled (spray) containers and syringes. Compositions described herein will
generally be administered directly to a t. Direct delivery may be accomplished by parenteral
injection (e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial
space of a tissue), or lly, such as by rectal, sublingual, oral (e.g. tablet, spray), vaginal,
topical, transdermal or transcutaneous, intranasal, ocular, aural, pulmonary or other mucosal
administration. Intramuscular administration is typical, as sed above.
The methods described herein may be used to elicit systemic and/or l
immunity, preferably to elicit an enhanced systemic and/or mucosal immunity.
Dosage can be by a single dose schedule or a le dose schedule. Multiple
doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule.
In a multiple dose schedule the various doses may be given by the same or different routes e.g. a
eral prime and mucosal boost, a mucosal prime and parenteral boost, etc.. Multiple doses will
typically be stered at least 1 week apart (e.g. about 2 weeks, about 3 weeks, about 4 weeks,
about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, etc.).
Immunogenic compositions described herein can be administered to the same patient every year,
every 2 years, every 3 years, etc.
Also envisaged is co-administration of different respiratory vaccines to a subject at
the same time e.g. to administer a pneumococcal vaccine at the same time as an influenza vaccine.
Combination vaccines, in which two or more vaccines are administered as a mixture, like combined
pneumococcal saccharides (conjugated or unconjugated) with a respiratory syncytial virus (RSV)
antigen, and is also speculated that a number of other antigens such as an influenza virus antigen
might be added. For example, the methods described herein may be d to the cture of a
combination vaccine comprising a combination of the fusion (F), attachment (G) and matrix (M)
proteins of RSV with an nza vaccine.
Also bed is the use of a vaccine composition or of a method for the
preparation of a vaccine composition, as above described, for immunizing mammal against natural
conformational antigen, ularly against influenza or RSV infections, or to e antibodies
directed against conformational antigen, such as HA, NA or RSV antigen. In one aspect, bed
is the use of a recombinant polypeptide described herein for the preparation of a vaccine or
immunogenic composition intended to prevent or to treat influenza or RSV infection.
The term “comprising” as used in this specification and claims means “consisting
at least in part of”. When interpreting statements in this specification, and claims which include the
term “comprising”, it is to be understood that other features that are additional to the features
prefaced by this term in each statement or claim may also be present. Related terms such as
“comprise” and “comprised” are to be interpreted in similar manner.
LEGENDS TO THE S
Figure 1. Schematic representation (panels A and B) and binding to BLPs (panels C and D), and
multimerization state (E) of various HA fusion proteins. Schematic representation of linear HAOMD-Protan
(panel A) that is able to form trimers (abbreviated as HA-Ptri ) and HA-Protan (panel
B) that exists as a monomer (abbreviated as HA-Pmon ). The OMD is the GCN4-pII. The Protan part
(=PBD) of the fusion varies in size. The number following the letter P in the abbreviated protein
fusion name indicates the number of LysM s in the Protan part. L1-2: linker sequences. The
L following the number in the iated protein fusion name indicates the presence of a C-
terminal linker domain after the most C-terminal LysM domain. LysM1-2: LysM (peptidoglycan
binding) domains.
Panels C and D show that only 1 LysM domain is required for efficient binding to BLPs when the
HA-Protan fusion ns contain a GCN4 domain (OMD). Three different HA-Protan fusion
protein variants without GCN4 trimerization motif and one such fusion protein containing a GCN4
motif were expressed in HEK293S (GNTI-) cells. This was done for HA proteins originating from
H1M (panel C) and from X31 (panel D) in duplicate. The HA-Protan fusion proteins obtained were
allowed to bind to BLPs by incubating 150µg (dry weight) of the les with an excess amount
of approximately 30-45µg of the fusion proteins after which the particles were collected. Then
50 µg of each BLP-fraction was analyzed by SDS-PAGE and Coomassie Blue ng s I].
As a control expression was checked by ing samples from the cell culture media by SDSPAGE
and Western blotting [panels II] using MAb PA90 (α-Protan). All fusion proteins were well
expressed. Together, these experiments show that a single LysM domain combined with an OMD
is ient for efficient binding of proteins to BLPs whereas two LysM domains are required for
efficient binding when no OMD is present. Panel E: OMD-containing HA-Protan fusion ns
are predominantly oligomeric. Analyses of different HA-GCN4-Protan variants by blue native gel
electrophoresis followed by n blot using the Protan dy α-PA90. Of each variant, equal
amounts of the cleared cell culture atant were boiled for 10 seconds (10’’), 30 seconds (30’’)
or 3 minutes (3’) before application to the gel. HA-Protan fusion proteins analyzed were the H1M
virus derived HA-P1tri and HA-P1Ltri proteins. All these HA proteins migrated with the mobility
corresponding to that of a trimer after very brief heating (10 sec), but dissociated into dimeric and
monomeric forms of HA after longer boiling times. HA-P1 tri and HA-P1Ltri s remained
detectable even after prolonged boiling of the samples. All the lent HA-Pmon variants
migrated with the mobility of a monomer. In addition, most of these HA-Pmon proteins exhibited a
variable, but sometimes strong tendency to form high molecular weight aggregates ated by
the asterisks), most likely as a result of the poor folding and stability of these non-native proteins.
Figure 2. Schematic presentation of HA-P2Ltri and tri variants and the binding thereof to
BLPs for the production of vaccines. Panel A: production of HA-P2Ltri and HA-P1Ltri results
mainly in trimeric variants but also low amounts of unwanted, not properly folded, ric
variants are produced. Panel B: binding of mono- and trimeric tri variants to BLPs followed
by subsequent washing results in BLP vaccines with bound native oligomeric HA and the
ed not properly folded monomeric HA. Binding of mono- and trimeric HA-P1Ltri variants to
BLPs followed by subsequent washing results in BLP vaccines with bound native eric HA
and without the unwanted not properly folded monomeric HA. Therefore, binding of proteins to
BLPs using a single LysM domain combined with an OMD such as GCN4 allows for selective
binding of the desired native biological active oligomeric proteins.
Figure 3. Amount of bound HA-Protan variants with and without OMD to BLPs. Increasing
s ( 0 – 4 µg) of HA-P1Ltri (H1-GCN4-P1L) and HA-P2Lmon (H1-P2L) were allowed to bind
to a fixed amount (0.3 mg) BLPs. After binding the amount of bound HA was ined. The
experiment was performed in duplicate. Clearly, more HA-P1Ltri binds to BLPs at similar
concentrations as used for HA-P2Lmon . Hence, binding of ns to BLPs using a single LysM
domain combined with an OMD such as GCN4 is more efficient than with two LysM domains
without an OMD.
Figure 4. eric HA (in contrast to monomeric HA) bound to BLPs is biologically functional
in an agglutination test. A. Schematic representation of the haemagglutination assay. Panel 1:
influenza virus mixed with red blood cells (RBCs; ery) are able to bind to RBCs and are able to
form networks that cause agglutination. Panel 2: HA trimers attached to BLPs (BLP-HAtri ) and
mixed with RBCs are able to bind to RBCs, and are able to form networks that cause agglutination.
Panel 3: HA monomers attached to BLPs (BLP-HAmon ) and mixed with RBCs are not able to bind
to RBCs, and are not able to form networks that cause agglutination; the RBCs sediment in wells of
a iter plate, which is visible as a dot. Panel 4: BLPs mixed with RBCs are not able to bind to
RBCs and do not cause agglutination. Panel 5: HA trimers (HAtri ) bind to RBCs, but are not able to
form in networks that cause agglutination.
B. Haemagglutination assay using turkey RBCs. The HA used in the fusions is H1M. Lane 1:
negative control, RBCs + buffer. Lane 2: RBCs + BLP. Lane 3: RBCs + BLP with 4 µg bound HAP1L
tri . Lane 4: RBCs + BLP with 2 µg bound HA-P1Ltri . Lane 5: RBCs + BLP with 1 µg bound
HA-P1L tri . Lane 6: RBCs + BLP with 0.5 µg bound HA-P1Ltri . Lane 7: RBCs + 4 µg HA-P1Ltri .
Lane 8: RBCs + BLP with 4 µg bound mon . Lane 9: RBCs + BLP with 2 µg bound HAP2L
mon . Lane 10: RBCs + BLP with 1 µg bound HA-P2Lmon . Lane 11: RBCs + BLP with 0.5 µg
bound HA-P2Lmon . Lane 12: RBCs + 4 µg HA-P2Lmon . This ment y shows that only
oligomeric HA bound to BLPs (BLP-HAtri ) is biologically functional, whereas monomeric HA
bound to BLPs Atri ) is not.
Figure 5. ity of HA-P1Ltri bound to BLPs. Panel A: HA-P1Ltri bound to BLPs (ratio 3.3 µg
HA-P1L tri bound to 1 mg BLPs) was aliquoted and stored at 2-8 °C. At T=0, 3, 6 and 9 months post
formulation an aliquot was tested for the amount of HA-P1Ltri bound to BLPs (amount measured at
T=0 set at 100%); and panel B: biological activity in an agglutination test. AU; agglutination units.
This experiment clearly shows that HA-P1Ltri bound to BLPs is completely stable and biological
onal up to at least 9 months of storage in PBS at 2-8 °C.
Figure 6. Average amount of anti-H1M IgG antibodies in µg/ml (panel A); HI titers (panel B)
present in the serum; and S-IgA (panel C) present in nose wash of mice immunized three times
intranasally with: (i) soluble trimeric HA (HAtri ) [0.33 µg per dose]; (ii) soluble trimeric HA mixed
with BLP (BLP+ HAtri ) [0.33 µg HAtri and 0.1 mg BLP per dose]; (iii) trimeric HA (HA-P1L tri )
bound to BLPs (BLP-HAtri ) [0.33 µg HAtri and 0.1 mg BLP per dose], and (iv) ric HA
(HA-P1L mon ) bound to BLPs (BLP-HAmon ) [0.33 µg HAtri and 0.1 mg BLP per dose]. Clearly, the
BLP-HA tri particulate formulation was the most immunogenic formulation as compared to soluble
trimeric HA (HAtri ) and soluble trimeric HA mixed with BLP (BLP+ HAtri ). With respect to
functional antibody assays (HI titers; panel B and S-IgA; panel C) the oligomeric BLP-HAtri
particulate formulation elicited higher responses than the monomeric mon particulate
formulation showing that biologically functional HAtri is the most immunogenic mation.
Figure 7. Expression and BLP g characteristics of HAtri -Protan, GCN4 (OMD) containing
fusion proteins with various Protan moieties. Panel A: HEK 293 cells were transfected with the
tive expression plasmids and incubated after which culture supernatants were harvested and
cells lysed. s of each were analyzed by SDS-PAGE and Western blotting, using an dy
directed against the Protan moiety (α-PA90). The production of a series of GCN4-containing HA
proteins (designated i to indicate their trimerization potential) of subtypes H3 (X31) and H1
(H1M) are shown. All HA-Ptri variants were readily expressed and efficiently secreted into the cell
culture medium as judged from their limited presence in the cell lysates. The X31 HA-Ptri fusion
proteins were produced somewhat less abundant than the H1M HA-Ptri fusion proteins, while in
general the HA proteins fused to P1L and P2L seemed to display the highest production levels with
the most limited retention in the cells. Panel B: different GCN4 containing HA-Protan fusion
ns were compared for their binding to BLPs by incubating equal s of the particles in
the presence of excess amounts of fusion proteins and analyzing the s of the BLP-bound
proteins by SDS-PAGE and Western blotting. All HA-Ptri ts were found to bind but with
markedly varying efficiencies. Both for the H1M and the X31 virus d HA proteins, variants
HA-P1 tri , HA-P1Ltri and HA-P2Ltri bound to the BLPs most efficiently. Low binding efficiency was
observed for the H1M1 and X31 HA-P2tri proteins to BLPs. This result tes that 1 LysM
domain in combination with an OMD is sufficient to enable excellent binding to BLPs. Panel C:
Western blot incubated with anti-HA (anti-H1M). Lane 1: marker proteins, sizes indicated in the
margin in kDa. Lane 2: BLP particles, 30 µg. Lane 3: HAtri , which carries a Strep tag (HA-Streptri )
instead of a Protan extension (40 ng). Lane 4: BLPs (30 µg) recovered from an incubation with
HA-Strep tri (840 ng). Lane 5: HA-P1Ltri , 44 ng. Lane 6: BLPs (30 µg) recovered from an
incubation with HA-P1Ltri (880 ng). Altogether these ments show that the fusion proteins are
well expressed and secreted from the mammalian cells and that the ce of the bacterial Protan
domain at the C-terminus did not interfere with efficient secretion of the HA-oligomeric fusion
proteins (panel A). Moreover, this experiment clearly shows that 1 LysM domain is sufficient to
obtain excellent binding to BLPs and that the GCN4 domain, while required to enhance the binding
of a single LysM domain, does not bind to BLPs (panel C).
Figure 8. Schematic representation (A), expression (B), multimerization state (C) and binding to
BLPs (D) of Protan-NA. Panel A: Schematic representation of linear Protan-OMD-NA that is able
to form tetramers (abbreviated as P-NAtet ) and Protan-NA that exists as a monomer viated as
P-NA mon ) fusions. The OMD is the GCN4-pLI in the NA constructs. The Protan part (=PBD) of the
fusion contains 1 LysM domain with or without linker. The L following the number in the
abbreviated protein fusion name indicates the presence of a C-terminal linker domain after the
LysM domain. Panel B: shows the expression of Protan-NA fusion proteins with or without GCN4
tetramerization motif. HEK 293 cells were transfected with the respective expression plasmids and
incubated after which culture supernatants were harvested and cells lysed. Samples of each were
analyzed by SDS-PAGE and Western blotting, using an antibody directed against the Protan
moiety (α-PA90). Similar to the HA-Protan proteins, all Protan-NA variants were found to be
secreted into the cell culture atant; minor intracellular ion was observed for the Protan-
NA variants ning the GCN4 tetramerization motif. Panel C: shows that OMD-containing
NA-Protan fusion proteins are oligomeric. Here the oligomeric state of P1L-NA variants with (+)
and without (-) GCN4 was compared. Samples of these P1L-NA variants were analysed by bluenative
gel electrophoresis. Most of the P1L-NAmon protein migrated as a monomer and part of it as
a dimer. However, no tetramer could be detected. In contrast, the P1L- NAtet protein migrated
according to a tetramer with no detection of monomers or dimers. Altogether these experiments
show that the NA fusion proteins are well expressed and secreted from the mammalian cells and
that the presence of the ial Protan domain at the N-terminus did not interfere with ent
secretion of the NA-oligomeric fusion proteins (as observed for gomeric fusion proteins
with Protan at the C-terminus). Moreover, the GCN4 motif induces and stabilizes the oligomeric
state in the NA fusion protein as was observed for HA fusion n. Panel D: different NA-Protan
fusion proteins were ed for their binding characteristics to BLPs. Protan P1 variants with or
without linker C-terminally of the LysM domain and with and without OMD (GCN4) were allowed
to bind to BLPs by incubating 150µg (dry ) of the particles with an excess amount of
approximately 30-45µg of the fusion ns after which the particles were collected (lanes
indicated with B). The lanes indicated with S show NA which remained in the medium after
binding. A mock incubation of BLPs with buffer was taken along as negative l. Then 5 µg of
the BLP-fraction was analyzed by SDS-PAGE and Western blot using rabbit A90 serum
(anti-Protan). No or poor binding was obtained for the mon and P1-NAmon fusion proteins
lacking a GCN4 tetramerization motif as was observed for the HA-P1mon constructs. However,
clearly ent BLP binding was observed with the tet fusion protein. In st, the P1-
NA tet construct that lacks a linker between the LysM domain and the OMD domain, showed poor
binding. Clearly, a single LysM motif is already sufficient for efficient binding of the oligomeric
Protan forms, provided that a linker domain is present between the LysM domain and the OMD.
Figure 9. Neuraminidase activity of NA variants. The neuraminidase variants P1 and P1L - both
without and with GCN4 - were tested for their neuraminidase activity using a fetuin-based
neuraminidase activity assay. Nunc MaxiSorp ates were coated overnight at 4°C with 100 µl
of 5-µg/ml fetuin. Hundred microliters of cell culture medium samples ning r amounts
of NA (as confirmed by western blotting) were serially diluted and added to the fetuin-coated wells.
After 1 h of incubation at 37°C, the plates were washed and inidase activity was
subsequently measured by adding peroxidase-labeled peanut agglutinin (2.5 µg/ml; Sigma),
incubating for 1 h at room temperature, washing the plates, and adding 100 µl of peroxidase
substrate (TMB) to each well. After 5 min, the reaction was stopped by the addition of 100 µl of 0.3
M phosphoric acid, and OD values were measured at 450 nm using an enzyme-linked
immunosorbent assay (ELISA) reader (EL-808 [BioTEK]). As shown by the graphs, the Protan-
NA tet proteins ning the GCN4 tetramerization motif exhibited a concentration dependent
sialidase activity. No ase activity was found for the Protan-NA fusion proteins lacking the
GCN4 tetramerization motif. These results clearly demonstrate that the eric forms of Protan-
NA are enzymatically functional.
Figure 10. Schematic entation (A and B) and expression and binding to BLPs (C) of various
F fusion proteins. Schematic representation of linear F-OMD-Protan (panel A) that is able to form
trimers (abbreviated as F-Ptri ) and F-Protan (panel B) that exists as a r (abbreviated as FPmon
). The OMD is the GCN4-pII sequence in the F ucts. The Protan part (=PBD) of the
fusion varies in size. The number following the letter P in the abbreviated protein fusion name
tes the number of LysM domains in the Protan part. L1-3: linker sequences. The L following
the number in the abbreviated protein fusion name indicates the presence of a C-terminal linker
domain after the most C-terminal LysM domain. LysM1-2: LysM (peptidoglycan g)
domains. In panel C different F-Protan fusion proteins with and without GCN4 were compared for
their binding to BLPs by incubating equal amounts of the particles in the presence of excess
amounts of fusion proteins and analyzing the amounts of the BLP-bound proteins by SDS-PAGE
and n blotting. The F-Ptri variant with one LysM and GCN4 domain and F-Pmon variant with
two LysM domains were found to bind efficiently to BLPs. Low binding efficiency to BLPs was
observed for the F-Pmon variant with one LysM domain but g GCN4. This result indicates that
1 LysM domain in combination with an OMD is sufficient to enable excellent binding of F proteins
to BLPs, similar to what is observed for HA and NA. To study expression of the Protan-F fusion
proteins, HEK 293 cells were transfected with the respective expression ds and incubated
after which culture supernatants were harvested and cells lysed. Samples of each were analyzed by
SDS-PAGE and Western blotting, using an antibody directed against the Protan moiety (α-PA90).
Similar to the HA-Protan and Protan-NA proteins, all F-Protan variants were found to be secreted
into the cell culture supernatant.
Figure 11. Trimeric F protein bound to BLPs (BLP-Ftri ) s Synagis®-like antibody responses
in mice after intranasal administration. Panel A; schematic representation of the Synagis®
competition ELISA. Wells of microtiter plates are coated with F protein. These wells are incubated
with two-fold serial dilutions of serum of vaccinated mice. After incubation serum dilutions are
removed by washing and the wells are subsequently incubated with non-saturating amounts of
Synagis ®. After incubation, non-bound Synagis® is erred to a second plate and, after binding,
detected using a secondary antibody. The amount of detected bound Synagis® is a measure of the
amount of Synagis®-like antibodies in the serum of the vaccinated mice. Panel B: result of the
ition ELISA, which clearly shows that Synagis®-like antibodies are elicited in the serum of
mice intranasally ated with BLP-Ftri .
Figure 12. Efficacy (panel A), serology (panel B) and safety (panel C) after intranasal ation
of cotton rats with ri . Cotton rats were immunized three times asally with a 14 day
al with: (i) soluble F (Fmon ) [4 µg per dose]; and (ii) trimeric F (F-P1Ltri ) bound to BLPs
(BLP-Ftri ) [4 µg HAtri and 0.5 mg BLP per dose], and (iii) PBS as a negative control. Intramuscular
formalin-inactivated RSV complexed with aluminium salts (FI-RSV) was given as an ed
disease control. At day 14 after the last vaccination all animals were challenged (i.n.) with
Long. Animals were bled for virus neutralization titers (VN) at day 0, 28 and 42. At day 5
post nge all animals were ated and the lungs harvested en bloc and bi-sect for viral
titration and histopathology to score enhanced e characteristics. Panel A shows a significant
reduction in virus titer after BLP-Ftri vaccination compared to Fmon or PBS vaccination. The low
virus titer coincided with the highest level of VN titers at day 28 and 42 (Panel B). Clearly, the
BLP-Ftri particulate formulation was the most immunogenic and protective formulation as
compared to soluble F (Fmon ) and PBS. Panel C: histopathology sections of the lungs of vaccinated
cotton rats were scored for interstitial pneumonia and alveolitis. BLP-Ftri vaccination followed by
RSV infection resulted only in a low lung histopathology score compared to the scores observed
after FI-RSV vaccination and subsequent RSV challenge. Clearly, the BLP-Ftri ulate
formulation does not induce enhanced disease in cotton rats.
________________________________________________________________________
___________________________________________________________________
EXPERIMENTAL N
Materials and Methods
1.1. Genes and expression vectors
Human codon optimized genes ng the haemagglutinin (HA) ectodomain (a.a. 17-522) of the
influenza viruses A/Aichi/2/68 H3N2 (X31) and A/California/04/2009 H1N1 (H1M), the
neuraminidase (NA) head domain (a.a. 75-469) of A/Mallard/Netherlands/2/2005 H5N2
(Taxonomy ID: 571469), and fusion protein (F) ectodomain of the respiratory syncytial virus
(RSV) subtype A, isolate GA7SA99VR360 (a.a. 26-513) were synthesized (GenScript) and cloned
into a pCD5 vector - a derivative of expression d S1-Ig (Li et al., Nature 426 [2003], 450-
454) - for expression in HEK293T cells.
The HA gene was flanked by sequences encoding N-terminally a CD5 signal ce and
C-terminally the artificial GCN4 trimerization sequence pII) (Harbury et al., Science 262
, 1401–1407) followed by one of four Protan domain variants (Figure 1A). Three of these
ucts proved to express and bind to BLPs well and for these variants a construct lacking the
trimerization sequence was also constructed (Figure 1B). The NA gene was flanked by sequences
encoding an N-terminal CD5 signal sequence followed by the P1 or P1L Protan domain and an
artificial GCN4 tetramerization sequence (GCN4-pLI) (Harbury et al., e 262 [1993], 1401–
1407) (Figure 8A). Based on these constructs, two additional constructs were ted lacking the
artificial GCN4 erization sequence (Figure 8A). The F gene was flanked by sequences
encoding N-terminally a CD5 signal sequence and C-terminally the artificial GCN4 trimerization
sequence (GCN4-pII) ry et al., Science 262 [1993], 1401–1407) followed by one Protan
domain (Figure 10A). Two constructs lacking a trimerization sequence ed by one or two
Protan domains were also constructed (Figure 10B).
1.2 Protein expression and binding to BLPs
HEK293T cells were transfected with the pCD5 expression vectors containing the HA, F or NA
encoding sequences using polyethyleneimine (PEI) in a 1:5 ratio (µg DNA : µg PEI). At 6 h post
transfection the ection medium was replaced by 293 SFM II expression medium (Invitrogen),
supplemented with sodium bicarbonate (3.7 g/liter), glucose (2.0 r), Primatone RL-UF (3.0
g/liter, Kerry ience, Zwijndrecht, The Netherlands), penicillin (100 units/ml), streptomycin
(100 , glutaMAX (Gibco), and 1.5% DMSO. Tissue culture supernatants were harvested 5–6
days post transfection. HA-Protan and Protan-NA protein expression was confirmed by Western
blotting using the Protan (LysM) specific polyclonal rabbit antiserum α-PA90 as a primary
antibody, a swine-α-rabbit conjugated with horse radish peroxidise (Dako) as secondary antibody
and detection using ECL™ (Amersham™, GE Healthcare).
Secreted HA-Protan, F-Protan or Protan-NA proteins were ively bound to BLPs by
adding 0.15 mg BLPs (dry weight) to an excess of cleared T expression culture
supernatant and incubating for 30 minutes at room temperature while mixing gently. BLPs with
bound n were then collected by low-speed fugation and the pellet was washed three
times with DPBS. Finally the pellet was ended in a volume of DPBS equal to the original
volume of BLPs added. Binding of the HA, F and NA fusion proteins to the BLPs was assessed by
SDS-PAGE and Western blotting using the α-PA90 antiserum, whereas the amount of BLP-bound
protein was determined by SDS-PAGE and subsequent Coomassie blue staining using purified
BSA as a nce protein.
The oligomeric state of the fusion proteins was determined by electrophoresis in bluenative
gels and uent Western blotting using α-PA90.
1.3 Biological characterization of recombinant HA-Protan and Protan-NA fusion proteins.
Biological activity of BLP-bound HA was assessed by haemagglutination assay using chicken or
turkey erythrocytes. Only with onal trimeric HA protein bound to their surface, BLPs will
mediate the formation of a network (‘mesh’) of cross-linked erythrocytes, a process known as
agglutination. Trimeric HA or BLP alone will not cross-link the erythrocytes. In the assay, 25 µl of
soluble HA-Protan, BLP-bound HA or BLPs was ly d in 25 µl DPBS + 1% BSA in a
96-well (V-shaped CellStar©, Greiner Bio-One). From the last dilution 25 µl was discarded in order
to obtain equal volumes in all wells. To all wells an equal volume of 0.5% chicken erythrocytes
was added, the suspensions were gently mixed and incubated for 45 minutes at 4°C to allow crosslinking
and/or precipitation of the erythrocytes.
Functionality of the soluble -NA fusion proteins was assessed using a fetuin solid
phase assay (Lambre et al. Clin. Chim. Acta [1991] 198:183-193). Nunc MaxiSorp 96-well plates
were coated overnight at 4˚C with 100 µl of 1 µg/ml fetuin. Cleared HEK293T expression culture
supernatants containing similar quantities of -NA fusion ns (based on amounts of
Protan as determined by Western ng) were serially diluted in PBS-Ca/Mg
[0.901mM/0.493mM] after which 100 µl of the mixture was added to the fetuin-coated wells. After
1 h incubation at 37°C, the plates were washed and neuraminidase activity was subsequently
measured by adding peroxidase-labelled peanut agglutinin (2.5 µg/ml; Sigma), incubating for 1 h at
room temperature, washing the plates and adding 100 µl of peroxidase substrate (TMB) to each
well. After 5 minutes, the reaction was stopped by the addition of 100 µl of 0.3 M oric acid
and OD values were measured at 450 nm using an ELISA reader (EL-808 [BioTEK]).
1.4 Immunizations of mice with oligomeric n formulations.
Four groups of ten female Balb/c mice of 6-8 week old were immunized three times intranasally
with a 10 day interval, with 4 different HA formulations (H1M): (i) soluble trimeric HA (HAtri ) [1
µg per dose]; (ii) soluble ic HA mixed with BLP (BLP+ HAtri ) [1 µg HAtri and 0.3 mg BLP
per dose]; (iii) trimeric HA (HA-P1Ltri ) bound to BLPs (BLP-HAtri ) [1 µg HAtri and 0.3 mg BLP
per dose], and (iv) monomeric HA (HA-P2Lmon ) bound to BLPs (BLP-HAmon ) [1 µg HAmon and 0.3
mg BLP per dose]. en days post the 3nd immunization, serum and nasal washes were
collected for ELISA analysis to determine the anti-H1M IgG (serum samples) and anti-H1M S-IgA
(nasal wash) se. For this purpose, plates were coated with 200 ng HA (H1M) per well. Serial
ons of the sera were incubated for 90 min and binding of H1M-specific IgG and IgA,
respectively, was detected using anti-mouse IgG and IgA-HRP conjugates (Southern Biotech). For
a calibration curve mouse IgG was diluted in triplicate (first well 0.5 µg/mL) (mouse IgG1, Sigma)
(only for serum IgG). After staining, the absorbency at 492 nm was determined in an ELISA
microtiter plate reader. To calculate the specific anti-HA IgG antibodies in serum (expressed in
µg/mL) the calibration curve is used (parameters of curve determined by 4-parameterfit). To
calculate the specific A IgA antibodies in nasal wash (expressed in titers which are the
ocal of the calculated sample dilution corresponding with an A492 =0.3 after background
correction) the parameters of the curve were determined by 4-parameterfit. HA-specific
haemagglutination tion titres (HI) were determined using serum collected on day 34 (each
individual animal) of each group. The serum samples were inactivated at 56 °C for 30 min and
subsequently overnight at RT incubated with kaolin to reduce a-specific haemagglutinin tion.
The kaolin treated samples were applied onto the plates in duplicate in serial two-fold dilutions
using a multichannel pipette and mixed with the appropriate homologous inactivated Influenza
virus (A/California/07/2009 (H1N1), 4 HAU; NIBSC, UK) and incubated for 40 min at RT.
Subsequently, a 1% guinea pig erythrocyte solution was added to each well. glutinin was
allowed to proceed for two hours and scored for the highest dilution at which haemagglutination
was observed.
Two groups of ten female Balb/c mice of 6-8 week old were immunized three times
intranasally with a 10 day interval, with 2 different BLP-Ftri formulations: (i) F bound to BLPs
(BLP- Ftri low) [0.6 µg Ftri and 0.5 mg BLP per dose]; and (ii) F bound to BLPs (BLP- Ftri high)
[2.2 µg Ftri and 0.5 mg BLP per dose]. Fourteen days post the 3rd zation, serum samples
were collected and pooled per group for a Synagis® competition ELISA analysis to determine the
level of Synagis®-like antibodies induced. For this purpose, plates were coated with 100 ng F per
well. Serial dilutions of the sera (including pre-immune serum) were incubated for 90 min followed
by a wash. Next, the plates were incubated with sub-saturating amounts of s®. After
incubation, non-bound s® was transferred to a second F coated plate and, after binding,
detected using a secondary anti-human IgG antibody. The color development was measured at 492
1.5 zations of cotton rats with oligomeric F-Protan and subsequent challenge with
RSV.
Four groups of 5 young adult cotton rats (6-8 weeks of age) were immunized three times with a 14
day interval with 4 different ations: (i) PBS (negative control), (ii) soluble monomeric F
(F mon ) [4 µg per dose]; (iii) trimeric F (F-P1Ltri ) bound to BLPs (BLP-Ftri ) [4 µg HAtri and 0.5 mg
BLP per dose], and (iv) formalin-inactivated RSV vaccine formulated in ium salts (FI-RSV)
[Lot#100 (1:125)]. Group 1 to 3 were vaccinated intranasally and group 4 intramuscularly.
At day 0, 28 and 42 serum was collected for virus neutralization analysis. For this e,
heat vated serum is serial diluted in a 96 well plate. To each well 25 to 50 plaque forming
units (PFU) is added. The dilution plates are incubated for 1 hour at 25-300C to allow the serum
s and virus to interact. Next the virus serum mix is transferred to HEp-2 cells for virus
titration. The cells are incubated with mix for 1h followed by the addition of a methyl cellulose
overlay. The cells are incubated 4 days at 370C after which the overlay is removed. Crystal violet
stain is added and d to fix for 2 to 4 hours at 25-300C. The stain is removed by rinsing with
cold water. Next the plates are allowed to air dry completely prior to reading. The number of
plaque forming units (PFU) per well using a dissecting microscope. At day 42 each animal were
challenged with 100 µL of RSV/A/Long at 105 pfu per animal. At day 5 post challenge the animals
were terminated and the lungs were harvested en bloc and bi-sect for viral titration (left section)
and histopathology (right section). Histopathology sections were scored for interstitial pneumonia
and alveolitis.
EXAMPLE 1. Expression of the HA-Protan, F-Protan and Protan-NA fusion proteins
In order to express soluble tan, F-Protan and Protan-NA ic proteins in mammalian
cells, the ectodomain-coding sequences were first cloned into appropriate expression vectors. In the
pCD5 vector expressing the HA-Protan fusion proteins, the HA-ectodomain sequence was
preceded by a signal peptide-encoding sequence, to allow efficient secretion of the recombinant
protein, and followed by a sequence encoding one of four Protan domain variants and an artificial
GCN4 trimerizaton motif (GCN4-pII; OMD) between the HA and Protan domain variants (Figure
1A). For the three HA-Protan fusion protein variants that were most efficiently expressed and
secreted (see below) we also constructed and expressed fusion proteins that lacked the GCN4
trimerization sequence (OMD; Figure 1B).
In the pCD5 vector expressing the Protan-NA chimeric proteins, the NA-head domain
sequence was preceded by a signal peptide-encoding sequence, to allow efficient secretion of the
recombinant protein, and by a sequence encoding a Protan domain variant (one LysM )
either with or t an artificial GCN4 tetramerizaton motif (GCN4-pLI; OMD) placed in
between the Protan domain and the NA sequence (Figure 8A).
In the pCD5 vector expressing the F-Protan fusion proteins, the F-ectodomain
sequence was preceded by a signal peptide-encoding sequence, to allow efficient secretion of the
recombinant n, and ed by a sequence encoding one LysM domain variant and an
artificial GCN4 trimerizaton motif (GCN4-pII; OMD) between the F and the LysM domain e
10A). We also constructed and expressed two F-Protan fusion proteins that lacked the GCN4
trimerization sequence (OMD) with one and two LysM domains, respectively e 10B).
sion of the HA-Protan, an and Protan-NA fusion proteins with or without
an artificial trimeric, trimeric or tetrameric GCN4 multimerization motif (OMD), respectively, was
achieved by transfection of the expression plasmids into HEK293 cells. Expression and secretion of
the HA-Protan, F-Protan and Protan-NA proteins was verified by subjecting cell culture
supernatants to gel electrophoresis followed by Western blotting using an antibody ed against
the Protan moiety (α-PA90). HA-Protan fusion ns and F-Protan fusion proteins ning the
GCN4 domain (OMD) are abbreviated HA-Ptri and F- Ptri , respectively, indicating the trimerization
potential of these fusion proteins. HA-Protan and F-Protan fusions lacking the GCN4 domain
(OMD) are abbreviated HA-Pmon and F-Pmon , respectively, indicating the monomeric state of the
proteins. Likewise, the Protan-NA fusions are abbreviated: P-NAtet for the variants containing the
GCN4 domain (OMD) indicating the tetramerization ial of the fusion n and P-NAmon
for variants lacking the GCN4 domain (OMD) indicating the monomeric state of the protein. All
HA-P variants of both X31 and H1M influenza virus derived HAs were readily expressed and
efficiently secreted into the cell culture medium with only minimal ion of the fusion protein
in the cells, as shown in Figure 7A for the HA-Ptri variants. The X31 HA-Ptri fusion proteins were
produced somewhat less abundant as compared to HA-Ptri ns of H1M. While HA-species
ences in sion levels may occur, in general it seems that HA fused to P1L and P2L
display the highest tion levels with the most limited ion of fusion protein in the cells
compared to the P1 and P2 variants, respectively. Similar to the HA-Protan proteins, all Protan-NA
and F-Protan variants were found to be secreted into the cell culture supernatant (Figure 8B and
10C). Only some limited intracellular retention was observed for the Protan-NA ts containing
the GCN4 erization motif (Figure 8B).
Clearly, the presence on the N- or C-terminus of the bacterial Protan domain variants did
not interfere with efficient secretion of the HA- and NA-oligomeric fusion proteins by the
mammalian expression cells.
EXAMPLE 2. Binding of HA-GCN-Protan, F-GCN-Protan and -GCN-NA fusion
proteins to BLPs
The binding characteristics of the s HA-Protan, F-Protan and Protan-NA fusion proteins to
BLPs were determined by comparing binding to BLPs in the presence of excess amounts of the
various Protan fusion proteins. The SDS-PAGE and Western ng analyses demonstrated that
all HA-Ptri variants bound. The GCN4 domain strongly enhances the binding properties of single
LysM domain (1L) constructs. This was demonstrated in an experiment with several HA-P
constructs that were bound to BLPs. Figure 1C and D show three tan variants lacking the
OMD GCN4 that were tested in duplicate: Protan variant P2Lmon , Protan variant P1Lmon and Protan
variant P1mon in comparison to the GCN4-containing HA-Protan fusion protein with Protan t
P1L tri . The results of the Coomassie staining (panels I) consistently demonstrate poor (H1M) or
hardly any (X31) binding when the extension ned just one LysM domain in the ric
constructs lacking a GCN4 domain (P1Lmon and P1mon ). More efficient binding ed when the
ric fusion protein had 2 LysM domains (P2Lmon ) as expected. In contrast, in case of the
HA-Protan fusion protein with GCN4, efficient binding was already achieved with 1 LysM domain
(P1L tri ). Clearly, unlike for monomeric HA-Protan fusion ns, a single LysM motif is already
sufficient for efficient binding of the trimeric tan forms.
In another experiment, the binding efficiency of an HA construct with a single LysM
domain combined with an OMD N4-P1L or HA-P1Ltri ) was compared with a monomeric
HA construct with two LysM domains (Figure 3). For this purpose, increasing amounts ( 0 – 4 µg)
of HA-P1Ltri and HA-P2Lmon which both showed efficient binding to BLPs (see Figure 1C/D) were
allowed to bind to a fixed amount (0.3 mg) BLPs. More HA-P1Ltri bound to BLPs at similar
concentrations as used for HA-P2Lmon . Hence, binding of proteins to BLPs using a single LysM
domain combined with an OMD such as GCN4 in an oligomeric construct is more efficient than
with two LysM domains in a monomeric construct.
In another experiment (Figure 5A) the stability of the binding of HA-GCN4-P1L to BLP
was assessed upon long term storage in PBS at 2-8oC. The data show that an HA uct with a
single LysM domain combined with an OMD remains stably bound to BLPs for at least 9 months.
This is in strong contrast to the observations of Raha et al. (2005) and Moeini et al. (2010) whose
ments showed a loss of proteins bound with single LysM domain to bacteria of over 40%
within 5 days of storage.
BLP-binding of the different Protan-NA and F-Protan fusion proteins corroborated the
observations with the HA constructs that a single LysM domain combined with an OMD results in
efficient binding. In Figure 8D and 10C, no or poor binding was obtained for the mon , P1-
NA mon and P1L-Fmon fusion proteins lacking a GCN4 multimerization motif as was observed for the
HA-P1 mon constructs. r, y efficient BLP binding was observed with the F-P1Ltri , FP2L
mon and P1L-NAtet fusion proteins.
As a control we showed that the OMD itself does not enable binding to BLP particles. For
this e, binding of HA-Streptri , which carries a Strep-tag instead of a Protan extension, and
HA-1L tri to BLP particles was compared. Figure 7C shows a Western blot in which HA-Streptri
(lane 3) was mixed with BLPs. The BLPs were red and loaded on the gel (lane 4). No
binding of HA-Streptri occurred. In st, efficient binding was observed for HA-1Ltri (compare
lanes 5 and 6).
In addition, both for the H1M (Figure 1C) and for the X31 virus derived HA proteins
(Figure 7B), variants HA-P1tri , HA-P1Ltri and HA-P2Ltri bound to the BLPs most efficiently. Low
binding ency was observed for the H1M1 and X31 HA-P2tri proteins to BLPs. This was also
observed for the P1-NAtet construct that lacks a linker between the LysM domain and the OMD
domain, which showed poor binding. y, a linker domain between the LysM domain and the
OMD is needed for proper binding to BLPs.
In the natural situation as observed in the monomeric AcmA, 3 consecutive intramolecular
LysM domains (in cis) facilitate efficient binding. Reduction of this number to 1 LysM domain
results in a strong reduction of g efficacy (Bosma et al. [2006]) and low stability (Raha et al.
and Moeini et al. [2010]). Taken together, our results indicate that a single LysM domain
can facilitate highly efficient and stable g to BLPs when placed in an multimeric
intermolecular conformation (LysM domains interacting in trans) where the subunits, each
containing a single LysM domain, are multimerized by an OMD. Moreover, a linker domain
present between the LysM domain and the OMD further increases the production and binding
efficacy.
The use of a single LysM domain has several advantages: (i) it reduces the size of the binding
domain and, (ii) it prevents binding of immunogenic inferior monomeric fusions as can still be the
case when 2 or more LysM domains are used (HA-P1Lmon does not bind vs mon binds to
BLPs, see Figure 1C and D, panels I and II; F-P1Lmon does not bind vs HA-P2Lmon binds to BLPs,
see Figure 10C). Hence, a single LysM domain tates the selective g of the immunogenic
most relevant (i.e. multimeric) forms of the fusion proteins (see Figure 2).
EXAMPLE 3. Functionality of the HA-GCN-Protan and Protan-GCN-NA fusion proteins
Oligomeric state of the fusion proteins
The oligomeric state of the tan and Protan-NA proteins with or without an artificial OMD,
the trimeric of tetrameric GCN4 multimerization motif, respectively, was analyzed by blue-native
gel electrophoresis. Samples of HA-Protan fusion proteins that had been shown to bind to BLPs,
i.e. the H1M virus derived HA-P1tri and HA-P1Ltri proteins were boiled for 10 seconds, 30 seconds
or 3 minutes in order to dissociate HA trimers. All the HA-Ptri proteins migrated in the gel with a
mobility ing to that of a trimer when heated briefly (boiling for 10 sec) and these HA-trimers
dissociated into dimeric and monomeric forms of HA after prolonged sample boiling (Figure 1E,
left panels). HA-P1tri and HA-P1Ltri s remained detectable even after prolonged boiling of the
samples. In contrast, all the equivalent HA-Pmon variants ed with the mobility of a monomer.
In addition, most of these n proteins exhibited a variable, but sometimes strong tendency to
form high molecular weight aggregates (Figure 1E, right , indicated by the asterisks), most
likely as a result of the poor folding and stability of these non-native proteins.
Samples of the P1L-NA variants with and without GCN4 were ed by blue-native gel
electrophoresis (Figure 8C). Most of the P1L-NAmon n migrated as a monomer, part of it as a
dimer, however no er could be detected. The P1L-NA tet protein migrated according to a
tetramer with no detection of monomers or dimers.
These data clearly demonstrate that the presence of an OMD such as the GCN4 motif is
required to obtain stable oligomeric proteins that have the native quaternary ure.
Biological activity of the fusion proteins
The biological activity of native HA as present in particles can be ed by a glutination
assay using erythrocytes (Figure 4A). With this assay the sialic acid receptor binding function of
the HA protein – a biological property only exhibited by trimeric HA - is assessed. In order to
demonstrate that agglutination in the described assay is critically dependent on the presence of HA
oligomers bound to BLPs rather than on HA monomers bound to BLPs, tri and HA-P2Lmon
(both H1M) were bound to BLPs. Figure 4B clearly shows that HA-P1Ltri bound to BLPs is able to
cause agglutination of the red blood cells in a concentration dependent way (lanes 3-6), while HAP2L
mon bound to BLPs is not able to cause agglutination (lanes 8-11). These results clearly show
that only oligomeric forms of HA bound to BLPs are biologically active.
The biological functionality of soluble monomeric and oligomeric P1-NA and P1LNA
proteins was studied by measuring their sialidase activity using a solid phase g assay
with the sialidated blood glycoprotein fetuin as the substrate. Desialylation by Protan-NA was
measured by means of the PNA lectin binding activity as detailed in the al and Methods
section. As shown in Figure 9, the Protan-NAtet proteins containing the GCN4 tetramerization motif
exhibited a concentration dependent sialidase activity. No sialidase activity was found for the
Protan-NA fusion proteins g the GCN4 tetramerization motif (P-NAmon ). These results
clearly demonstrate that the oligomeric (but not the monomeric) forms of Protan-NA are
functional.
In sion, biologically active, soluble trimeric HA and soluble tetrameric NA
proteins fused to different Protan variants were efficiently produced in mammalian cells. Efficient
binding to BLPs was already ed with 1 LysM domain, provided that the fusion protein
ned an OMD, such as the GCN4 oligomerization domain; in other words, efficient binding
mediated by a single LysM domain depends on – and s for - the proteins occurring in a
oligomeric state. Furthermore, the proteins bound in their oligomeric state to the BLP demonstrate
a biological activity that is similar to the native proteins.
EXAMPLE 4. Immunogenicity of oligomeric HA-Protan in ulate form
The immunogenicity of ic HA (HA-P1Ltri ) bound to BLPs (BLP-HAtri ) was evaluated after
two intramuscular administrations in mice. The HA subtype used was H1M. The BLP-HAtri
ulate formulation was compared to e trimeric HA (HAtri ) and soluble trimeric HA
mixed with BLP (BLP+ HAtri ). The amount of HAtri in the formulations was 0.33 µg per dose. Ten
days post 2nd immunization serum was collected and pooled per group for ELISA analysis to
determine the anti-H1M IgG response. The results in Figure 6A clearly show that BLP-HA
particulate formulations were the most immunogenic formulation with respect to serum HA-
specific IgG responses as compared to soluble trimeric HA (HAtri ) and e trimeric HA mixed
with BLP (BLP+ HAtri ). Highly relevant however, is the observation (Figure 6B) that the trimeric
HA bound to BLPs (BLP-HAtri ) elicits higher functional antibody titers compared to monomeric
HA bound to BLPs (BLP-HAmon ) measured as hemagglutination inhibition (HI) titers. In addition,
only trimeric HA bound to BLPs (BLP-HAtri ) elicits significant levels of HA-specific secreted IgA
(S-IgA) in the mucosal secretions of the nose (Figure 6C). These results are most likely a reflection
of the proper folding and onality of the trimeric HA bound to BLPs (BLP-HAtri ).
Hence, particulate BLP formulations that contain bound native oligomeric antigen
compositions, ished through the use of an OMD and a single LysM domain, are highly
immunogenic and elicit more potent, and a qualitatively more relevant response than soluble
oligomeric and monomeric bound ations.
EXAMPLE 5. Immunogenicity, efficacy and safety of oligomeric F-Protan in particulate
form
The immunogenicity of trimeric F (HA-P1Ltri ) bound to BLPs (BLP-Ftri ) was evaluated after three
intranasal administrations in mice. Three doses (0.6 and 2.2 µg per dose) of the BLP-Ftri particulate
formulation were used. Ten days post 3rd zation, serum was collected and pooled per group
for a Synagis® competition ELISA analysis (Figure 11A) to ine the anti-F antibody
response. In this assay, antibodies elicited in the mice by the vaccines that bind to F epitopes
recognized by the neutralizing Synagis® antibody, prevent the binding of Synagis®. Thus the
measured amount of und Synagis® in the assay is a measure of Synagis®–like antibodies
raised by the vaccines. The results in Figure 11B clearly show that the trimeric F bound to BLPs
(BLP-Ftri ) s Synagis®–like antibodies in a dose dependent manner. Pre-immune sera were
ve, as expected.
In conclusion, ulate BLP formulations that contain bound native oligomeric F
antigen, established h the use of an OMD and a single LysM domain, are highly
immunogenic and elicit neutralizing-type antibodies.
The cotton rat closely recapitulates the devastating pathological outcome, known as
enhanced disease, associated with the RSV-vaccine failure in the 1960’s. In the 1960s, trials in
infants were ted in the USA with formalin-inactivated RSV vaccine formulated in
aluminium salts V). During subsequent l RSV exposure, the rate of the virus infection
in infants who received the vaccine was no less (and was perhaps even greater) than that in control
group immunised with parainfluenza vaccine. Most remarkably, 80% of RSV vaccinees needed
hospitalisation, whereas only 5% of such ions among control parainfluenza vaccinees
required admission to the hospital. Two of the vaccinated infants died. Thus, rather than protecting,
FI-RSV was an infamous vaccine candidate that primed young infants for exacerbated disease upon
exposure to natural RSV ion. Administration of FI-RSV to cotton rats followed by RSV
infection s in compareble enhanced (lung) pathology characterized by interstitial pneumonia
and alveolitis . For this reason safety testing (absence of ed disease) of a concept RSV
vaccine in cotton rats is essential step in RSV vaccine development.
The efficacy and safety (lack of enhanced disease symptoms) of trimeric F (HA-P1Ltri )
bound to BLPs (BLP-Ftri ) was evaluated after three intranasal administrations in cotton rats and was
compared to monomeric F (Fmon ). The capacity of the serum antibodies raised by the vaccines to
inhibit RSV replication was determined in virus neutralization assays in s taken 14 days
after each vaccine administration. For the evaluation of safety, formalin-inactivated RSV vaccine
formulated in ium salts (FI-RSV) was given uscularly to an additional group of
animals. FI-RSV is known to elicit pathology in the lungs of cotton rats that is related to signs of
enhanced disease (interstitial pneumonia and alveolitis). Fourteen days after the final
immunizations each animal was challenged with RSV. At day 5 post challenge the s were
terminated and the lungs were harvested for determination of virus , virus lization titers
and g of interstitial pneumonia and alveolitis by histopathology. The results clearly show
(Figure 12A) that trimeric F (HA-P1Ltri ) bound to BLPs (BLP-Ftri) is more efficacious in reducing
the lung viral titers as compared to ric F (Fmon ). This observation correlates very well with
the higher virus neutralizing capacity of sera from animals immunized with BLP-Ftri compared to
that of Fmon (Figure 12B). antly, the increased efficacy of the ic F (HA-P1Ltri ) bound to
BLPs (BLP-Ftri ) is associated with lack of signs of enhanced disease (interstitial pneumonia and
alveolitis in the , which is typical for the use of FI-RSV in this model (Figure 12C).
In conclusion, particulate BLP formulations that contain bound native oligomeric F
antigen, established through the use of an OMD and a single LysM domain, are highly efficacious,
elicit virus neutralizing antibodies and have a favourable safety profile.
In this specification where reference has been made to patent ications, other external
documents, or other sources of information, this is generally for the purpose of providing a context
for discussing the features of the invention. Unless specifically stated otherwise, reference to such
external documents is not to be construed as an admission that such documents, or such sources of
information, in any jurisdiction, are prior art, or form part of the common general knowledge in the
art.
In the description in this specification reference may be made to subject matter that is not
within the scope of the claims of the current application. That subject matter should be readily
identifiable by a person skilled in the art and may assist in putting into practice the ion as
defined in the claims of this application.
Claims (29)
1. An immunogenic composition in particulate form, comprising: i. a non-viable bacterium-like particle (BLP) ed from a Gram-positive bacterium as particulate carrier; ii. oligomers of a recombinantly produced polypeptide attached non-covalently to said BLP, wherein the recombinant polypeptide comprises: A) an N- or C-terminal antigenic domain, comprising at least one surface exposed ptide of pathogenic or tumour origin, or antigenic part thereof, the antigenic domain being fused to B) an oligomerization domain (OMD), said oligomerization domain being fused via C) a linker domain to D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain mediating the non-covalent attachment of the polypeptide to the BLP, and wherein the polypeptide as a whole ns only a single copy of a LysM domain; and iii. a pharmaceutically acceptable t or excipient.
2. Immunogenic composition according to claim 1, wherein the e exposed polypeptide in the antigenic domain of said recombinant ptide comprises an ectodomain of an enveloped virus protein, preferably wherein said virus is nza virus, animal virus, human respiratory coronaviruses, human immunodeficiency virus (HIV), or paramyxovirus, in particular respiratory syncytial virus (RSV) or metapneumovirus.
3. Immunogenic composition according to claim 2, wherein the surface exposed polypeptide or antigenic part thereof is selected from the group consisting of nza lutinin (HA) ectodomain or part thereof, influenza neuraminidase (NA) ectodomain or part thereof, coronavirus spike (S) protein ectodomain or part thereof, RSV glycoprotein F or G ectodomains or parts thereof and HIV gp140 ectodomain or part thereof.
4. Immunogenic composition according to any one of the preceding claims, wherein said linker domain of said recombinant polypeptide consists of between 10 and 60, preferably 20-50, more preferably 25-40 amino acids, for instance about 30 amino acids.
5. Immunogenic composition according to claim 4, wherein the linker domain ses an amino acid ce selected from the group consisting of : GASSAGNTNSGGSTTTITNNNSGTNSSST, GSASSTNSGGSNNSASTTPTTSVTPAKPTSQ QSAAASNPSTGSGSTATNNSNSTSSNSNAS.
6. Immunogenic composition according to any one of the preceding claims, wherein the oligomerization domain (OMD) of said recombinant polypeptide is a dimerization, ization or tetramerization domain, preferably wherein said oligomerization domain is selected from a GCN4- based di-, tri- or tetramerization , the C-terminal domain sequence of T4 fibritin (foldon) or functional part or analog thereof (C-terminal 27 to 30 residues) and the soluble trimerization domain of chicken cartilage matrix (CART) protein.
7. Immunogenic composition according to any one of claims 1-6, wherein the recombinant polypeptide furthermore comprises, in case of an N-terminal antigenic domain a C-terminal capping ce, or in case of a C-terminal nic domain an N-terminal capping sequence.
8. genic composition ing to any one of the preceding claims, wherein said bacterium is a non-pathogenic bacterium, preferably a food-grade bacterium, more preferably wherein said bacterium is selected from the group consisting of a Lactococcus , a Lactobacillus , a Bacillus and a Mycobacterium ssp.
9. Immunogenic composition according to any one of the preceding claims, wherein the ulate carrier is provided non-covalently with at least a first oligomer of ptides comprising surface exposed polypeptides or nic parts thereof derived from a first pathogen and a second oligomer of polypeptides comprising surface exposed polypeptides or antigenic parts thereof derived from a second pathogen.
10. Method for ing an immunogenic composition according to any one of claims 1 to 9, comprising the steps of: a) providing a recombinant polypeptide as recited in any one of claims 1-7, sing culturing a host cell comprising an expression vector encoding said polypeptide in a suitable medium allowing for expression of the polypeptide, and isolating the polypeptide; b) providing a non-viable bacterium-like particle (BLP) obtained from a Gram-positive ium. c) allowing for non-covalent binding of said ptide(s) to said BLP to form an immunogenic complex comprising oligomers of a surface exposed polypeptide of pathogenic origin or antigenic part thereof bound non-covalently to a particulate carrier, d) formulating the immunogenic x into an immunogenic composition.
11. An immunogenic composition prepared by the method of claim 10.
12. A use of an immunogenic composition as claimed in any one of claims 1-9 and 11 in the manufacture of a ment.
13. A use of an immunogenic composition according to any one of claims 1-9 and 11, in the manufacture of a medicament for eliciting an immune response against a pathogen in an individual in need thereof.
14. A use according to claim 13, for eliciting an immune response against a viral disease in an individual in need thereof.
15. A use as claimed in claim 14, wherein the viral disease is caused by influenza virus, animal coronavirus, human atory coronaviruses, human immunodeficiency virus (HIV), or paramyxovirus, in particular respiratory syncytial virus (RSV) or metapneumovirus.
16. A inant polypeptide comprising: A) an N- or C-terminal antigenic domain, comprising at least one surface d polypeptide or antigenic part thereof, the antigenic domain being fused to B) an oligomerization domain (OMD), said oligomerization domain being fused via C) a linker domain to D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain capable of mediating the non-covalent attachment of the polypeptide to a peptidoglycan carrier le being a non-viable bacterium-like le (BLP) obtained from a Gram-positive bacterium, and wherein the polypeptide as a whole contains only a single copy of a LysM domain.
17. A recombinant polypeptide as d in claim 16 wherein the at least one surface exposed polypeptide is of pathogenic or tumor cell .
18. A nucleic acid sequence ng a polypeptide according to claim 16 or 17.
19. A vector comprising a nucleic acid sequence according to claim 18.
20. A host cell, comprising a nucleic acid sequence ing to claim 18 or a vector according to claim 19, with the o that the host cell is not present in a human.
21. A host cell as claimed in claim 20 wherein said host cell is a eukaryotic host cell.
22. A host cell as claimed in claim 21, n said eukaryotic host cell is a mammalian host cell.
23. An immunogenic composition as claimed in claim 1 or 11 substantially as herein described or exemplified and with or without reference to the accompanying drawings.
24. A method as claimed in claim 10 substantially as herein described or exemplified and with or without reference to the accompanying drawings.
25. A use as claimed in claim 12 or 13 substantially as herein described or exemplified and with or without reference to the accompanying drawings.
26. A recombinant polypeptide as claimed in claim 16 substantially as herein described or ified and with or without nce to the accompanying drawings.
27. A nucleic acid sequence as claimed in claim 18 substantially as herein described or exemplified and with or without reference to the accompanying drawings.
28. A vector as claimed in claim 19 substantially as herein described or exemplified and with or without reference to the accompanying drawings.
29. A host cell as d in claim 20 substantially as herein described or exemplified and with or without reference to the accompanying drawings.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11159233 | 2011-03-22 | ||
EP11159233.3 | 2011-03-22 | ||
PCT/NL2012/050177 WO2012128628A1 (en) | 2011-03-22 | 2012-03-22 | Immunogenic compositions in particulate form and methods for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ615721A NZ615721A (en) | 2015-07-31 |
NZ615721B2 true NZ615721B2 (en) | 2015-11-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9585953B2 (en) | Immunogenic compositions in particulate form and methods for producing the same | |
US20240165218A1 (en) | Self-asssembling nanostructure vaccines | |
CA2849822C (en) | Novel influenza hemagglutinin protein-based vaccines | |
US20120052082A1 (en) | Cross-protective influenza vaccine | |
US20100111996A1 (en) | Papaya Mosaic Virus-Based Vaccines for Influenza | |
JP2016501196A (en) | Trimer before fusion with RSVF | |
CA2900489A1 (en) | Combination vaccine for respiratory syncytial virus and influenza | |
KR20230107621A (en) | Protein-based nanoparticle vaccine against metapneumovirus | |
US20220175910A1 (en) | Novel influenza antigens | |
US20230218739A1 (en) | Vaccine compositions, methods, and uses thereof | |
Sączyńska | Influenza virus hemagglutinin as a vaccine antigen produced in bacteria | |
JP2023523423A (en) | Vaccine against SARS-CoV-2 and its preparation | |
NZ615721B2 (en) | Immunogenic compositions in particulate form and methods for producing the same | |
RU2811439C2 (en) | Self-assembled nanostructured vaccines | |
Rigter et al. | A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant |